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Abstract 
 
Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase that is 
primarily expressed by cells of hematopoietic lineage. Syk acts downstream of 
immunoreceptor tyrosine-based activation motif–coupled receptors, including the B-cell 
receptor (BCR) and FcRs, and influences diverse biological events, such as cytokine 
production, degranulation, differentiation, and proliferation, suggesting that Syk is 
profoundly involved in the development of autoimmune diseases, allergic diseases, and 
malignancies. For example, direct injection of Syk small interfering RNA (siRNA) into 
the limb joints prevents joint swelling in models of autoantibody-induced arthritis. 
Regarding the relationship with allergic reactions, Syk-deficient mast cells fail to 
degranulate and secrete mediators when stimulated through FcεRI. Furthermore, Syk 
silencing by siRNA leads to a dramatic decrease of cell viability of B-cell chronic 
lymphocytic leukemia. Considering its biological actions and association with the 
pathogenesis of inflammatory diseases and B-cell malignancies, pharmacologic 
inhibition of Syk represents a potential therapeutic intervention option for patients with 
these diseases. Indeed, several ATP-competitive Syk inhibitors, notably fostamatinib, 
have already been evaluated in clinical trials performed in patients with autoimmune 
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diseases, including rheumatoid arthritis (RA) and immune thrombocytopenic purpura 
(ITP). Even though fostamatinib was efficacious against chronic refractory ITP, it is 
unclear whether inhibition of Syk activity specifically contributed to the clinical 
response and adverse events observed in the clinical trials, as this drug inhibits several 
kinases, including vascular endothelial growth factor receptor (VEGFR) 2 and Janus 
kinase (JAK) 2. Another Syk inhibitor, entospletinib, has been developed for the 
treatment of leukemia, but it inhibits multiple protein kinases within 100-fold of its 
inhibitory concentration 50 (IC50) value for Syk. These findings suggest that novel Syk 
inhibitors with different activity profiles from the above-mentioned inhibitors are 
required to provide new therapeutic options. Against this background, we tried to 
identify a novel, potent, and selective orally available Syk inhibitor. Investigation of 
structure-activity relationships led to identification of TAS05567 from chemically 
synthesized Syk inhibitory compounds. We characterized the profile of TAS05567 using 
biochemical assays as well as cell-based assays and showed its therapeutic potential for 
autoimmune diseases in Chapter 1. We further assessed the therapeutic potential of our 
compound for other diseases, including type 1 allergic diseases as well as B-cell 
malignancies, using preclinical animal models in Chapter 2. TAS05567 potently 
inhibited the activity of Syk, showing an average IC50 of 0.37 nM in enzymatic assays. 
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TAS05567 was more potent than R406 (an active metabolite of fostamatinib), exhibiting 
an average IC50 of 13 nM. The specificity of TAS05567 for Syk was determined at 50 
nM (approximately 140 times the IC50 value) using a panel of 192 kinases. In these 
analyses, TAS05567 only showed >70% inhibition of Syk and 4 other kinases, while 
R406 at 500 nM (approximately 40 times its IC50 for Syk) showed >70% inhibition of 
43 kinases. In addition, the IC50 values of TAS05567 and R406 were determined for 
VEGFR2 and JAK2. Whereas TAS05567 showed at least 10-fold selectivity for Syk 
over the 4 kinases, R406 showed equal or greater efficacy against these kinases. Next, 
we evaluated the effectiveness of TAS05567 in blocking the BCR-dependent signaling 
cascade using B-cell line. TAS05567 was marked inhibition of the phosphorylation of 
BLNK (IC50 = 1.8 nM), PLCγ2 (IC50 = 23 nM), and Erk1/2 (IC50 = 9.8 nM) induced 
by anti-IgM. TAS05567 also showed stronger inhibition of these molecules in the 
BCR-dependent signaling cascade than R406. In addition, we evaluated the inhibitory 
effects of TAS05567 on FcγR-mediated TNF-α release by macrophages. TAS05567 
showed concentration-dependent inhibition of TNF-α production by IgG stimulation. 
Syk also contributes directly to bone resorption in RA via its kinase activity–mediated 
regulation of receptor activator of nuclear factor kappa-B (RANK) signaling pathway 
that is essential for differentiation of osteoclasts. TAS05567 strongly inhibited the 
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formation of mature osteoclasts induced by M-CSF and RANKL in a 
concentration-dependent manner. 
 Next, to further investigate the potential therapeutic value of TAS05567 for 
autoimmune diseases, we evaluated its effects in representative rodent models of 
arthritis, collagen antibody-induced arthritis (CAIA) and collagen-induced arthritis 
(CIA). TAS05567 inhibited the development of arthritis based on clinical scores of 
CAIA or hind paw volume in CIA. Additionally, serum biomarker (MMP-3, IgG, and 
COMP) levels were significantly lower in the TAS05567 groups than in the vehicle 
group. In the experiment of rat CIA, we performed histopathologic examination of the 
left and right hind paws. TAS05567 significantly reduced inflammatory cell infiltration 
into the synovium and pannus formation and markedly ameliorated damage to cartilage 
and bone. At the same time, we monitored changes in body weight during treatment as 
an index of general toxicity and assessed red blood cell count and hemoglobin levels 
because anemia was observed in some patients during clinical trials of drugs with JAK2 
inhibition. TAS05567 did not significantly reduce body weight, the red blood cell count 
or hemoglobin level compared with control rats. Furthermore, we examined whether 
TAS05567 could attenuate platelet count decreases in mice with thrombocytopenia 
induced by administration of an antiplatelet antibody, because Syk is profoundly 
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involved with the pathogenesis of ITP via the activation of FcγR. In mice injected with 
an anti-CD41 antibody, the platelet count decreased by more than 50% compared with 
sham mice. In this model, TAS05567 provided significant protection against anti-CD41 
antibody–induced thrombocytopenia in a dose-dependent manner. We evaluated the 
therapeutic effects of TAS05567 on other indications, including type 1 allergic diseases 
as well as B-cell malignancies, using in vitro assay as well as preclinical animal models. 
Syk reportedly plays a crucial role in FcεR-mediated production of chemical mediators 
by mast cells. Therefore, we evaluated the inhibitory effects of TAS05567 on 
IgE-induced histamine release by RBL-2H3 cells. TAS05567 suppressed histamine 
release by IgE stimulation in a concentration-dependent manner. We next examined 
whether TAS05567 is a potent drug for treatment of B-cell malignancies, we confirmed 
cytotoxic activity of our compound toward diffuse large B-cell lymphoma (DLBCL) 
cells, which depend on chronic active BCR signaling for survival. TAS05567 reduced 
the cell viability of several DLBL cell lines in a concentration-dependent manner. 
Furthermore, to examine whether TAS05567 could suppress the type 1 allergic reactions 
in vivo, we used 2,4,6-trinitrophenol (TNP) -IgE transgenic mice. Administration of 
picryl chloride to the ears of the mice provoked ear swelling, which reached a peak 2 h 
after antigen challenge. TAS05567 strongly suppressed ear swelling from 1 to 4 h after 
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antigen challenge. Finally, the in vivo antitumor activity of TAS05567 was evaluated in 
SCID mice bearing SU-DHL-10 xenograft. TAS05567 significantly inhibited the tumor 
growth and decreased the levels of EGR2 mRNA and phosphorylation of BLNK in the 
tumor tissues, as compared with vehicle control. 
We determined the pharmacologic profile of a novel selective Syk inhibitor, TAS05567, 
which potently inhibited BCR signaling, FcR-dependent cellular functions, osteoclast 
differentiation, and proliferation of DLBCL cells. After oral administration, TAS05567 
not only was ameliorated symptoms in animal models of several inflammatory diseases, 
but also suppressed tumor growth in the mouse xenograft model using DLBCL cells. 
Notably, TAS05567 showed less off-target activity, such as VEGFR2 and JAK2 
inhibition, than R406, suggesting that the efficacy/toxicity profiles of our Syk inhibitor 
and fostamatinib differ. Our data suggest that TAS05567 would be an efficacious novel 
treatment for inflammatory diseases as well as B-cell malignancies. 
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 General Introduction 
 
Uncontrolled immune responses that attack either self-tissues and/or innocuous 
environment antigens lead to autoimmune diseases and allergic conditions. 
Epidemiological researches provide evidence that autoimmune diseases prevalence 
has grown throughout the last century, mostly in the western world [1-3]. RA is a 
representative autoimmune disease characterized by systemic inflammatory disorder 
affecting approximately 1% of the world’s population that causes chronic synovial 
inflammation and joint destruction [4]. Disease-modifying anti-rheumatic drugs 
(DMARDs) with potential immunosuppressant activity, such as methotorexate, 
sulfasalazine, and cyclosporine, are available for the management of RA, but an 
American College of Rheumatology (ACR) 50 response (based on standard criteria for 
assessing RA symptoms) is only achieved in approximately half of all patients and an 
ACR 70 response is attained by a minority [5]. Although biological drugs, including 
anti-tumor necrosis factor (TNF)-α antibody and anti-interleukin (IL)- 6 antibody, and 
Janus kinase (JAK) inhibitors have proved effective for active RA in recent clinical 
trials, there are still unmet clinical needs because these agents are associated with 
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antibody production and adverse events, such as an increased risk of infection or 
malignancy [6-8]. Therefore, new therapies with stronger efficacy and a better safety 
profile are needed for RA patients who have severe symptoms or are refractory to 
treatment with conventional DMARDs or biological agents. 
  Autoimmune diseases, including RA, are caused by aberrant immune responses that 
generally involve production of autoantibodies against auto-antigens [9, 10]. Various 
immune cells, including B-cells, monocytes, macrophages, neutrophils, and dendritic 
cells, express receptors for the Fc portion of immunoglobulins (Igs) [11, 12]. During the 
chronic inflammatory process of RA, immune complexes (ICs) formed by autoantigens 
and autoantibodies are deposited in synovial tissues and activate effector cells through 
the Fc gamma receptor (FcγR), leading to cytokine production, synovial inflammation, 
and joint damage [13]. The importance of autoantibodies in the pathogenesis of RA is 
also supported by current treatments, e.g., suppression of pathogenic antibody 
production by depleting B cells with rituximab has been shown to be effective for RA 
[14, 15]. In addition, passive transfer of antibodies targeting type II collagen produces 
pathologic joint changes in mice resembling those in human RA [16]. Importantly, mice 
lacking FcγR do not develop inflammatory joint changes or symptoms after antibody 
transfer [17, 18], which suggests that targeting the FcγR signaling pathway is a potential 
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therapeutic strategy for preventing the progression of RA. 
  ITP is an autoimmune bleeding disorder caused by the improper functioning or 
destruction of platelets. Incidence of ITP has been estimated to be from 0.46 to 
12.5/100,000 person-years in children and from 1.6 to 3.9/100,000 person-years in 
adults [19]. There is an estimate of approximately 3,000 new cases of this disorder in 
Japan every year [20]. Since 1974, ITP has been specified as an intractable disease in 
Japan, and some patients have received public financial support from the national 
governments. Circulating platelets are opsonized by platelet-specific autoantibodies, 
resulting in their premature destruction by macrophages. [21]. Many ITP patients show 
a good response to current treatments, such as steroids and splenectomy, but a small 
group remains at risk of life-threatening cerebral hemorrhage due to a persistent low 
platelet count [22, 23]. Similar to RA, ICs have been implicated in the pathogenesis of 
ITP because intravenous immunoglobulin (IVIg) targeting FcγR is effective in patients 
with ITP [24], and because injection of antibodies against platelet surface antigen to 
mice decreases the platelet count like the pathogenesis of human ITP [25]. Based on 
these findings, the FcγR signaling cascade has become an attractive target for treatment 
of ITP. 
  Other types of inflammatory diseases, such as allergic diseases, are caused by an 
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ineffective tolerogenic immune response towards allergens. Similar to autoimmune 
diseases, the prevalence of allergic diseases are increasing worldwide, particularly in 
low and middle income countries [26]. Although therapies for allergic diseases have 
improved over the years with the introduction of agents directed against the 
inflammatory processes, those therapies have remained, for the most part, non-curative 
[27]. In particular, type 1 allergic diseases such as urticaria, asthma, and allergic rhinitis 
are predominantly caused and exacerbated by IgE-mediated allergic reactions [28, 29]. 
Antigen-induced cross linking of IgE-bound FcεRI leads to activation of mast cells and 
basophils followed by release of a variety of biochemical mediators, such as histamine 
and arachidonic acid metabolites [30]. Importantly, FcεRI-deficient mice fail to develop 
increased inflammatory responses even after repeated exposure to antigen [31]. 
Omalizumab, a monoclonal antibody that inhibits the interaction between IgE and 
FcεRI, has been shown effective in patients with severe allergic asthma [32]. Therefore, 
targeting the FcεRI signaling pathway is a promising therapeutic option for type 1 
allergic diseases. 
  Spleen tyrosine kinase (Syk) is a 72 kDa non-receptor cytoplasmic tyrosine kinase 
that is primarily expressed by cells of hematopoietic lineage [33]. Syk acts downstream 
of immunoreceptor tyrosine-based activation motif–coupled receptors, including the 
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B-cell receptor (BCR), FcRs, and integrin signaling, and influences diverse biological 
events, such as cytokine production, degranulation, differentiation, and adhesion [34, 
35], suggesting that Syk is profoundly involved in the development of autoimmune and 
allergic diseases. For example, direct injection of Syk siRNA into the limb joints or 
genetic deficiency of Syk in hematopoietic cells prevents joint swelling and bone 
erosion in models of type II collagen autoantibody-induced arthritis [36, 37]. In addition, 
Syk-deficient macrophages show severely impaired phagocytosis of IgG-opsonized 
particles in response to FcγR activation [38]. Besides its crucial role in inflammation, 
Syk contributes directly to bone resorption in RA, because Syk kinase activity regulates 
RANK, which is the receptor for the RANKL signaling pathway that is essential for 
differentiation and activation of osteoclasts [39]. Regarding the relationship with 
allergic reactions, Syk-deficient mast cells fail to degranulate and secrete mediators 
when stimulated through FcεRI [40]. Considering its biological actions and its 
association with the pathogenesis of autoimmune and allergic diseases, pharmacologic 
inhibition of Syk represents a potential therapeutic intervention option for patients with 
these diseases. 
  In another aspect, Syk is also a key factor in the pathogenesis of B-cell malignancies 
because chronic activation of the BCR pathway is crucial for proliferation and survival 
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of malignant B cells [41]. Actually, Syk protein is activated in approximately half of 
primary human diffuse large B-cell lymphoma (DLBCL) tissues, the most common 
non-Hodgkin's lymphoma that develops from the B-cells in the lymphatic system [42]. 
DLBCL is known to be aggressive, with poor prognosis without adequate therapy. 
While 5-year survival rates in the first-line setting range from 60% to 70%, 40%-50% of 
patients remain refractory to the therapy [43]. Therefore, new therapeutic drugs are 
needed to improve survival. Of note, genetic knock down of Syk causes cell-cycle arrest 
and decelerates the proliferation of the Syk-positive DLBCL cells [42]. From these 
findings, Syk inhibitors have potential as therapeutic drugs for not only autoimmune 
and allergic diseases but also B cell malignancies including DLBCL (See below figure). 
 
 
 
 
 
 
  
  Indeed, several ATP-competitive Syk inhibitors, notably fostamatinib (Rigel 
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Pharmaceuticals), have already been evaluated in clinical trials performed in patients 
with autoimmune diseases, including RA and ITP [44]. Even though fostamatinib was 
efficacious against chronic refractory ITP [45], it is unclear whether inhibition of Syk 
activity specifically contributed to the clinical response and adverse events observed in 
the clinical trials, as this drug inhibits several kinases, including vascular endothelial 
growth factor receptor (VEGFR) 2 and Janus kinase (JAK) 2 [46, 47]. Another Syk 
inhibitor (GS-9973, entospletinib, Gilead Sciences) has been developed for the 
treatment of leukemia including DLBCL, but it inhibits multiple protein kinases within 
100-fold of its inhibitory concentration 50 (IC50) value for Syk [48]. These findings 
suggest that novel Syk inhibitors with different activity profiles from the 
above-mentioned inhibitors are required to provide new therapeutic options. Against 
this background, we tried to identify a novel, potent, and selective orally available Syk 
inhibitor. We synthesized a series of potent and highly selective ATP-competitive novel 
inhibitors of Syk. Investigation of structure-activity relationships led to identification of 
TAS05567 as a lead compound. 
  In this study, the pharmacological properties and utility of TAS05567, a novel Syk 
inhibitor, were investigated for the purpose of clarifying the difference with the 
preceding Syk inhibitors. In Chapter 1, we employed biochemical assays and cell-based 
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assays to characterize the basic features of TAS05567. In addition, we performed 
pharmacodynamics analyses to predict its in vivo activity using specimens from animals.  
Moreover, we examined the therapeutic potential of TAS05567 for autoimmune 
diseases using two types of rodent arthritis models as well as a passive 
antibody-induced ITP model. In Chapter 2, to assess the therapeutic potential of 
TAS05567 against allergic diseases and B-cell malignancies, we first evaluated the 
inhibitory activity of TAS05567 against histamine release and cell proliferation of 
cancer cells. Furthermore, we determined whether TAS05567 could suppress type I 
allergic reactions using IgE-mediated dermatitis model. Finally, we evaluated the 
antitumor activity of TAS05567 in subcutaneous xenograft tumors of human DLBLC 
cells. 
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Chapter 1 
Identification of pharmacological properties of TAS05567 and its therapeutic 
potency against autoimmune diseases 
 
1.1 Introduction 
  RA is a complex systemic inflammatory autoimmune disease characterized by 
excessive and chronic inflammation in joints, associated with synovial hyperplasia and 
with cartilage and bone destruction [49, 50]. Though activation of T cells can produce 
several proinflammatory cytokines, activation of B cells, autoantibody production, 
immune complex formation, and its deposition within the synovium are also profoundly 
involved in the pathogenesis of this disease [51, 52]. ITP is also an autoimmune disease 
in which autoantibodies against antigens on platelets result in the opsonization and 
phagocytosis of platelets by macrophages [21].  
Syk tyrosine kinase is essential for signaling from the BCR as well as FcR, and thus 
profoundly associated with autoantibody responses [34, 35]. Currently, several small 
molecule inhibitors targeted towards activity of Syk kinase have been developed for 
patients with immune-mediated inflammatory diseases [53]. Fostamatinib, a 
representative inhibitor of Syk, shows inhibitory effects on activity of Syk kinase in an 
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enzymatic assay and Ig-mediated signaling cascades as well as proinflammatory 
cytokine production in cell-based assays [46]. R406, an active metabolite of 
Fostamatinib, also exhibits significant efficacy in some preclinical models of 
autoimmune diseases, such as collagen-induced arthritis (CIA) and anti-CD41 
antibody-induced thrombocytopenia [45, 54]. Of note, Fostamatinib produces clinically 
significant responses in patients with chronic ITP who had relapsed or not responded to 
splenectomy and thrombopoietic agents [55]. The Food and Drug Administration (FDA) 
has approved fostamatinib as a second-line treatment for patients with chronic ITP 
following insufficient response to a previous therapy, based on the results of clinical 
trials. Fostamatinib also provides some clinical benefits to patients with active RA 
receiving methotrexate treatment in a 3-month, placebo-controlled trial [56]. However, 
it is unclear whether inhibition of Syk activity specifically contributed to reduction of 
symptoms in patients with autoimmune diseases, because Fostamatinib inhibits several 
other kinases, including VEGFR2 and JAK2, which are associated with the potential 
risk of hypertension and anemia [46, 47, 57, 58]. Indeed, hypertension was more 
frequent in the Fostamatinib group than in the placebo group during clinical trials for 
RA, and also anemia was observed in the lymphoma patients treated with this drug [59, 
60]. Moreover, adverse events such as elevation in transaminase enzymes and increase 
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in incidence of infection have been reported in patients receiving fostamatinib, which 
may be related to off-target inhibition of this drug [61]. Since these adverse events may 
limit the use of fostamatinib in the clinical setting, Syk inhibitors with a different profile 
from fastamatinib are expected to produce a benefit to patients with autoimmune 
diseases. 
  In this chapter, we first assessed the potency and selectivity of TAS05567 by a wide 
range of biochemical assays as well as Ig-mediated intracellular signaling pathway 
analyses by using R406 as a comparator. In addition, Syk-mediated cellular functions, 
such as production of proinflammatory cytokines associated with the pathogenesis of 
RA and differentiation of osteoclasts, were evaluated by in vitro experiments. Moreover, 
we determined the plasma protein binding of TAS05567 using mouse, rat, and human 
plasma to investigate whether there were species differences in plasma protein binding 
ratio of it. We further examined pharmacodynamics and pharmacokinetics of TAS05567 
using mice and rats to determine dosage of our compound for in vivo experiments. In in 
vivo studies, we evaluated the effects of TAS05567 on synovial inflammation, bone 
destruction, and serum markers associated with the pathogenesis of RA using CAIA and 
CIA that have been recognized as representative models of RA. Regarding the 
tolerability and safety of TAS05567, body weight changes and anemia risk were 
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assessed in a study using the rat CIA model. Finally, to investigate the therapeutic 
potential of TAS05567 in ITP, we utilized anti-CD41 antibody-induced 
thrombocytopenia model, which is based on a self-antigen that is highly relevant to the 
human disorder [25]. 
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1.2 Materials and Methods 
1.2.1 Reagents 
TAS05567, 3-(((3R, 4R)-3-aminotetrahydro-2H-pyran-4-yl) 
amino)-5-((2-(tert-butyl)-7-methyl-2H-indazol-5-yl) amino)-1, 2, 
4-triazine-6-carboxamide, was designed and synthesized by Taiho Pharmaceutical Co., 
Ltd. R406 was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
Prednisolone was purchased from Sigma-Aldrich, Co. (St. Louis, MO, USA). 
Polyglobin® N 10% (IVIg) was obtained from Japan Blood Products Organization 
(Tokyo, Japan). For in vitro experiments, TAS05567 and R406 were dissolved in 
dimethyl sulfoxide. R788, a prodrug of R406, was purchased from Medchemexpress 
LLC (Princeton, NJ, USA).  
1.2.2 Biochemical Assays 
The Off-chip Mobility Shift Assay was employed for measurement of kinase 
inhibitory activity. Recombinant FLT3, JAK2, VEGFR2, Syk, and RET (Carna 
Biosciences, Kobe, Japan) were used for activity assays in 20 mM HEPES buffer (pH 
7.5) with 0.01% Triton X-100 and 2 mM dithiothreitol. Each recombinant kinase was 
reacted with the appropriate peptide substrate in the presence of ATP (at room 
temperature (RT), followed by measurement of the product ratio using the LabChipTM 
system (PerkinElmer, Waltham, MA, USA). The selectivity of TAS05567 was assessed 
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with a panel of 192 kinases using the Profiler Pro kit (PerkinElmer) according to the 
manufacturer’s instructions. The plates were read using a LabChip EZ Reader 
(PerkinElmer). 
1.2.3 Off-target receptor binding assays 
TAS05567 was tested at 10 µM for orthosteric radioligand displacement against a 
panel of 68 primary molecular targets, such as G-protein-coupled receptors, ion 
channels, and transporters, to characterize its specificity using the LeadPrifilingScreen 
commercial assay (Eurofins Panlabs Taiwan, Taipei, Taiwan). Results that show an 
inhibition or stimulation >50% were considered to represent significant effects on the 
test compound. 
1.2.4 Detection of B-cell Linker Protein (BLNK), Phospholipase C (PLC) γ2, and 
Extracellular Signal-regulated Kinase (ERK) Phosphorylation (Ramos cells) 
A human B cell lymphoma cell line (Ramos, ATCC CRL-1596) was purchased from 
the American Type Culture Collection (Manassas, VA, USA) and maintained in Roswell 
Park Memorial Institute (RPMI) -1640 medium (Sigma-Aldrich) containing 10% fetal 
bovine serum (FBS). Ramos cells (1 × 105 cells/100 µl) were pretreated with test 
compounds, followed by stimulation with goat F(ab’)2 anti-human IgM (5 µg/ml; 
Southern Biotech, Birmingham, AL, USA) for 5 min at 37°C. The cells were then fixed 
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in Phosflow fix buffer I (BD Biosciences, San Jose, CA, USA) for 10 min at 37°C and 
permeabilized in Phosflow perm buffer III (BD Biosciences) for 30 min on ice. After 
membrane permeabilization, the cells were washed in staining buffer (FBS) (BD 
Biosciences) and resuspended and incubated for 1 h at RT in the same buffer containing 
phycoerythrin (PE) -labeled mouse anti-BLNK (pY84) (clone J117-1278), Alexa Fluor 
647–labeled mouse anti-PLCγ2 (pY759) (clone K86-689.37), and Alexa Fluor 488–
labeled mouse anti-ERK1/2 (pT202/pY204) (clone 20A) (all from BD Biosciences). 
Subsequently, the cells were washed and resuspended in staining buffer (FBS). 
Phosphorylation of BLNK, PLCγ2, or ERK1/2 induced by anti-IgM antibody was 
quantified using a flow cytometer (BD Biosciences). 
1.2.5 FcγR- and Lipopolysaccharide-mediated Tumor Necrosis Factor (TNF)-α 
Production Assay 
To assess FcγR-mediated TNF-α production, an Immulon 4 HBX 96-well plate 
(Thermo Fisher Scientific, Waltham, MA, USA) was coated overnight at 4°C with 100 
µg/ml of purified human IgG (R&D Systems, Minneapolis, MN, USA), and was 
washed with phosphate-buffered saline (PBS) (−) (Wako Pure Chemicals, Osaka, Japan). 
Next, THP-1 cells (ATCC TIB-202) were seeded into the IgG-coated plate at a density 
of 2 × 106 cells /ml and incubated for 4 h at 37°C. To measure lipopolysaccharide 
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(LPS)-mediated TNF production, THP-1 cells were seeded at the same density and 
pretreated with TAS05567 for 1 h, followed by stimulation with LPS (1 µg/ml, 
Sigma-Aldrich) for 24 h at 37°C. The TNF-α level in the supernatant was determined by 
ELISA (R&D Systems). 
1.2.6 FcγRI-mediated Phagocytosis Assay 
Phagocytic ability was evaluated by measuring the amount of uptake of latex beads 
coated with FITC-labeled IgG into cells by a phagocytosis assay kit (Cayman Chemical, 
Ann Arbor, MI, USA) according to the instruction manual. Briefly, RAW264.7 cells 
(ATCC TIB-71) were seeded in 6-well plates (1 ×106 cells/well) in DMEM containing 
5% FBS overnight at 37°C to allow adherence to the plate. On the next day, the latex 
beads were added directly to the culture medium at a dilution of 1:500 and incubated at 
37°C for 4 h. The cells were collected and analyzed by flow cytometry (BD 
Biosciences). 
1.2.7 Stimulation with an Inflammasome Activator 
THP-1 cells were differentiated by incubation with 0.2 µM PMA (Sigma-Aldrich) for 
3 days at 37°C and were seeded overnight at 37°C in a 96-well plate (2×104 cells/well) 
in RPMI-1640 containing 10% FBS to allow adhesion. On the next day, the cells were 
primed with LPS (1 µg/ml) in serum-free RPMI-1640 for 3 h and then pretreated with 
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TAS05567 for another 1 h at 37°C. Subsequently, the cells were stimulated with 
Imject™ Alum Adjuvant (30 µg/ml; Thermo Fisher Scientific) for 9 h at 37°C, and the 
IL-1β level in the supernatant was determined by ELISA (R&D systems). 
1.2.8 Differentiation of Osteoclasts  
Primary human osteoclast precursor cells (Lonza, Walkersville, MD, USA) were 
cultured according to the manufacturer’s instructions. Next, 33 ng/ml of macrophage 
colony-stimulation factor (M-CSF) and 66 ng/ml of RANKL (Lonza) were added to the 
culture medium (OCP BulletKit® Lonza; containing 10% FBS). After differentiation of 
osteoclasts, staining was performed on day 5 using a tartrate-resistant acid phosphate 
(TRAP) staining kit (Cosmo Bio, Tokyo, Japan), and the number of mature osteoclasts 
(TRAP-positive multinucleated cells >100 µm in diameter) per well was determined by 
manual counting.  
1.2.9 Experimental Animals 
All animal experiments were approved by the Animal Experiments Ethics Committee 
of Taiho Pharmaceutical Co., Ltd. The animals used for the present study were BALB/c 
(female and male) mice, male DBA1/J mice, female C57BL/6J mice, female Lewis rats, 
and male Sprague-Dawley rats from Charles River Laboratories Japan (Yokohama, All 
animals were housed in cages and maintained under a 12-h light/dark cycle with water 
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and food supplied ad libitum. During the experimental period, animals were observed to 
assess activity, feeding, and signs of pain in accordance with the established protocol. 
For administration, TAS05567 was dissolved in a solution of 0.5% hydroxypropyl 
methyl cellulose (Shinetsu Chemical, Tokyo, Japan) with 0.1 N HCl, and prednisolone 
was suspended in a solution of 0.5% HPMC without HCl. R788, a prodrug of R406, 
was used for in vivo experiments. R788 was dissolved in 0.1% carboxymethylcellulose, 
0.1% methylparaben–0.02% propylparaben–99.78% water, according to a previous 
report [45]. IVIg (500 mg/50 ml) was administered by intravenous injection at a volume 
of 10 ml/kg.  
1.2.10 BLNK Phosphorylation in Whole Blood 
For analysis of phosphor-BLNK in mice, blood samples were collected into heparinized 
tubes from non-immunized male BALB/c mice (7-9 weeks old) and then aliquots of the 
blood (80 µl) were transferred to test tubes. TAS05567 was added for 30 min at the 
indicated concentrations prior to stimulation with goat anti-mouse IgD (1:100, Thermo 
Fisher Scientific) for 10 min at 37°C, and stimulation was suppressed by addition of 
Lyse/Fix Buffer (BD Biosciences) according to the manufacturer’s protocol. Fixed cells 
were incubated overnight at 4°C with PerCP-conjugated anti-mouse CD45R/B220 
antibody (Clone RA3-6B2) (BD Biosciences) and PE-conjugated anti-BLNK antibody 
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(pY84) (clone J117-1278). For the experiment in rats, blood samples were collected into 
heparinized tubes from male Sprague-Dawley rats (7-8 weeks old) and then aliquots 
(180 µl) of the blood were transferred to test tubes. TAS05567 was added for 1 h prior 
to stimulation with anti-rat IgD (20 µg/ml, Thermo Fisher Scientific), and stimulation 
was suppressed by addition of Lyse/Fix Buffer (BD Biosciences). Fixed cells were 
incubated for 1 h at RT with FITC-conjugated ant-rat CD45RA antibody (clone OX-33) 
(BD Biosciences) and PE-conjugated anti-BLNK antibody (pY84) (clone J117-1278). 
Phosphorylation of BLNK induced by anti-IgD antibody was quantified using a flow 
cytometer (BD Biosciences).  
1.2.11 Plasma protein binding 
TAS05567 (in 50:50 acetonitrile/water) was tested at a final concentration of 1 µM in 
mouse, rat (Charles River Laboratories Japan, Yokohama, Japan), and human plasma 
(Biopredic, Rennes, France). An aliquot of 150 µl plasma containing TAS05567 was in 
donor side of the well of 96-well micro-equilibrium dialysis device (HTD 96b, 
HTDialysis, CT, USA). An aliquot of 150 µl PBS was added in reservoir side of the 
same device. The plate containing plasma and buffer was equilibrated at 37°C for 6 h, 
with constant shaking at 80 rpm on an orbital shaker. Samples were collected from 
respective sides after 6 h. All samples were centrifuged at 850g for 5 min at 4°C, and 
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then were analyzed by liquid chromatography–tandem mass spectrometry. Data are 
presented as mean ± SD (n = 3).  
1.2.12 BLNK Phosphorylation in Whole Blood 
For analysis of phosphor-BLNK in mice, blood samples were collected into 
heparinized tubes from non-immunized male BALB/c mice (7-9 weeks old), and then 
aliquots of the blood (80 µl) were transferred to test tubes. TAS05567 was added and 
incubated for 30 min at the indicated concentrations prior to stimulation with goat 
anti-mouse IgD (1:100, Thermo Fisher Scientific) for 10 min at 37°C. Stimulation was 
suppressed by addition of Lyse/Fix Buffer (BD Biosciences) according to the 
manufacturer’s protocol. Fixed cells were incubated overnight at 4°C with 
PerCP-conjugated anti-mouse CD45R/B220 antibody (Clone RA3-6B2) (BD 
Biosciences) and PE-conjugated anti-BLNK antibody (pY84) (clone J117-1278).  
For the experiment male Sprague-Dawley rats (7-8 weeks old), blood samples were 
collected into heparinized tubes, and then aliquots (180 µl) of the blood were transferred 
to test tubes. TAS05567 was added and incubated for 1 h prior to stimulation with 
anti-rat IgD (20 µg/ml, Thermo Fisher Scientific), and stimulation was suppressed by 
addition of Lyse/Fix Buffer (BD Biosciences). Fixed cells were incubated for 1 h at RT 
with FITC-conjugated ant-rat CD45RA antibody (clone OX-33) (BD Biosciences) and 
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PE-conjugated anti-BLNK antibody (pY84) (clone J117-1278). Phosphorylation of 
BLNK induced by anti-IgD antibody was quantified using a flow cytometer (BD 
Biosciences).  
1.2.13 Pharmacokinetics 
TAS05567 was orally administered to male BALB/c mice at 10 mg/kg (dosing 
volume of 10 ml/kg), and blood samples were collected with a heparinized syringe at 
0.5, 1, 2, 4, and 6 h after administration. In addition, TAS05567 was orally administered 
to male Sprague-Dawley rats at 10 or 25 mg/kg (dosing volume of 10 ml/kg), and blood 
samples were collected at 1, 2, 4, 8, and 24 h after administration. The blood samples 
were centrifuged at 10,000g for 5 min at 4°C to obtain plasma, which was stored at 
−80°C until use. Plasma drug concentrations were determined by liquid 
chromatography–tandem mass spectrometry. 
1.2.14 Mouse Model of Collagen Antibody-induced Arthritis (CAIA)  
On day 0, female BALB/c mice (7-8 weeks old) were intravenously injected with 2 
mg of an arthritogenic cocktail containing 5 monoclonal antibodies (Chondrex, 
Redmond, WA, USA), followed by intraperitoneal injection of LPS (100 µg) on day 4. 
Mice were randomly divided into vehicle, prednisolone, and TAS05567 groups, and the 
test drugs were administered daily from day 0. Arthritis was assessed on days 0, 3, 6, 
32 
 
and 9 by using the following clinical scoring system: 0, normal paw; 1, one swollen 
digit; 2, more than one swollen digit; 3, swelling of the entire paw; 4, swelling of the 
paw and all digits. The maximum possible score was 16 (4 x 4 paws). Serum MMP-3 
levels were determined by ELISA (R&D Systems). 
1.2.15 Mouse Model of Collagen-induced Arthritis (CIA)  
On day -21, male DBA/1 mice (7 weeks old) were anesthetized with isoflurane and 
0.1 ml of complete Freund’s adjuvant (BD Biosciences) containing 2 mg/ml bovine type 
II collagen (Collagen Research Center, Tokyo, Japan) was injected at one site on the 
back. For booster immunization, the mice were injected with 0.1 ml of incomplete 
Freund’s adjuvant (BD Biosciences) containing 2 mg/ml bovine type II collagen at one 
site on the tail under anesthesia on day 0. Oral administration of TAS05567 was 
initiated on day 0 of the study and continued to day 14. Arthritis was assessed on days 0, 
4, 7, 10, and 14 by the same criteria as those used for grading CAIA. The serum level of 
anti-bovine type II collagen IgG was determined by ELISA (Chondrex).  
1.2.16 Rat Model of Established CIA  
On day -14, female Lewis rats (7 weeks old) were anesthetized with isoflurane and 
injected with incomplete Freund’s adjuvant (BD Biosciences) containing 2 mg/ml 
bovine type II collagen at nine sites on the back and two on the tail (0.1 ml per site), 
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followed by booster injection at 2 sites on the tail (0.1 ml per site) on day -7. Oral 
administration of TAS05567 and prednisolone was initiated on day 1 of the study and 
continued to day 14. The volume of both hind paws was measured on days 1, 7, and 14 
by water displacement using a plethysmometer for rats (MK-101P; Muromachi Kikai, 
Tokyo, Japan). Body weight was also measured every day to monitor toxicity. At the 
end of the experiment, blood samples were collected for measurement of the red blood 
cell count and hemoglobin using a hematology autoanalyzer (Sysmex XT-2000iV; 
Sysmex, Kobe, Japan). In addition, the serum level of cartilage oligomeric matrix 
protein (COMP) was determined by enzyme-linked immunosorbent assay with a kit 
from Immunodiagnostic Systems (Boldon, UK) and both hind paws were harvested for 
histopathological examination. 
1.2.17 Histopathological examination 
Rat hind limbs were decalcified in formalin with 10% formic acid (Wako Pure 
Chemical Industries, Tokyo, Japan) and embedded in paraffin blocks, which were cut 
into sections, stained with hematoxylin-eosin (H&E), and randomly selected for 
microscopic examination. Then the hind limb joints were evaluated by assigning a 
histopathological score for each of four pathological changes (inflammation, pannus, 
cartilage damage, and bone damage) on a 5-grade scale from 0 to 4 (0 = normal and 4 = 
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the most severe changes). The histopathological scores for each pathological change 
were summed for both hind limbs to calculate the total score per animal (maximum: 8 
points). 
1.2.18 Mouse Model of Immune Thrombocytopenia  
Female C57BL/6J mice (8 weeks old) received TAS05567 orally on days 1 and 2. In the 
IVIg group, mice were injected intravenously with IVIg (1 g/kg) on day 1, followed by 
intravenous injection of 2 µg of anti-CD41 antibody (clone MWReg30, Thermo Fisher 
Scientific) in 0.2 ml of PBS on day 2. On day 3, 200 µL of peripheral blood was 
collected in a K2EDTA-coated Microtainer tube (BD, Franklin Lakes, NJ, USA), and 
the platelet count was determined with a Sysmex XT-2000iV hematology autoanalyzer 
(Sysmex). 
1.2.19 Statistical Analysis 
Statistical analysis and determination of half-maximal inhibitory concentration (IC50) 
values were performed with EXSUS software, version 8.0.0 (CAC Exicare, Tokyo, 
Japan). Results are reported as the mean ± standard deviation (SD) for in vitro 
experiments or the mean ± standard error of the mean (SEM) for in vivo experiments.  
Evaluation of the efficacy of TAS05567 in the rodent inflammation models was 
performed by using Dunnet’s test, while the statistical significance of differences in 
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histopathological scores was assessed with Steel’s test. In all analyses, P<0.05 was 
considered to indicate statistical significance. 
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1.3 Results 
1.3.1 Potency and Selectivity of TAS05567 
The chemical structure of TAS05567 is shown in Figure 1A. TAS05567 potently 
inhibited the activity of Syk, showing an average IC50 (mean ± SD) of 0.37 ± 0.029 nM 
in enzymatic assays in the presence of ATP concentration close to the Km value. 
TAS05567 was more potent than R406, exhibiting an average IC50 of 13 ± 0.26 nM 
under the same condition. The specificity of TAS05567 for Syk was determined at 50 
nM (approximately 140 times the IC50 value) using a panel of 192 kinases. In these 
analyses, TAS05567 only showed >70% inhibition of Syk and 4 other kinases (Figure 
1B and Table 1). In comparison, R406 at 500 nM (approximately 40 times its IC50 for 
Syk) showed >70% inhibition of 43 of the 192 kinases. During clinical trials of 
fostamatinib in patients with RA, adverse events such as hypertension, neutropenia, and 
anemia were considered to be related to inhibition of VEGFR2 and JAK2 [46, 47]. 
Accordingly, the IC50 values of TAS05567 and R406 were determined for 4 selected 
kinases, including VEGFR2 and JAK2. Whereas TAS05567 showed at least 10-fold 
selectivity for Syk over the 4 kinases, R406 showed equal or greater efficacy against 
these kinases (Table 2). In addition, the enzymatic assays of Syk as well as the selected 
4 kinases were performed at 1 mM ATP to approximate cellular concentrations. In the 
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presence of a physiologically relevant ATP concentration, TAS05567 inhibited Syk 
activity with IC50 of 1.5 ± 0.40 nM, but much less activity against the 4 kinases (Table 
2). Furthermore, the selectivity of TAS05567 for non-kinases targets was evaluated 
using a Panlabs Lead Profiling screen. In this assay, TAS05567 at 10 µM only inhibited 
1 of the 68 targets tested (inhibition of radioligand binding >50%) (Table 3). 
 
 
 
 
 
 
 
Figure 1. Selectivity of TAS05567 and R406 against a panel of 192 kinases.  
(A) Chemical structure of TAS05567. (B) TAS05567 and R406 were evaluated using 
the Profiler Pro kit. Values represent percent inhibition at 50 nM (TAS05567; 
approximately 140-fold the IC50 value of Syk kinase) and at 500 nM (R406; 
approximately 40-fold the IC50 value of Syk kinase). Inhibitory activity of 70% is 
shown as a dashed line. 
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Table 1. Selectivity profile of TAS05567 and R406 for kinase from the Profiler Pro Kit. 
Enzyme TAS05567 
Enzyme TAS0556
7 
% inh at 
50 nM 
R406 % 
inh at 
500 nM 
Enzyme TAS0556
7 
% inh at 
50 nM 
R406 % 
inh at 500 
nM 
Enzyme TAS0556
7 
% inh at 
50 nM 
R406 
% inh 
at 500 
nM 
ABL 1 20 EPHB3 2 25 NuaK1 31 87 
Abl(H396P) -11 -3 EPHB4 2 21 p38a 2 27 
Abl(Q252H) -17 -7 Erk1 -1 14 p38alpha/SAPK2
a (T106M) 
-11 -4 
Abl(T315I) -55 -36 Erk2 3 30 p38-beta2 -2 13 
ABL1(E255K) -15 -6 Fer 55 96 p38-delta  4 36 
ABL1(G250E) -16 -7 FES 2 27 p38-gamma -1 14 
ABL1(Y253F) -12 -5 FGFR1 -3 11 p70S6K 0 17 
AKT1 13 68 FGFR1 
(V561M) 
-19 -16 PAK2 1 20 
AKT2 0 17 FGFR2 2 24 PAK3 9 56 
AKT3 -1 14 FGFR2(N549
H) 
-18 -8 PAK4 77 100 
ALK 62 99 FGFR3 -3 9 PAK5 (PAK7) 80 100 
AMPK 3 29 FGFR3 
[K650E] 
-18 -14 PASK -5 2 
AMPK-alpha2/
beta1/gamma1 
0 17 FGFR4 -5 3 PDGFR beta -1 15 
Arg -3 9 FGR -7 1 PDGFR_alpha 4 32 
AurA  10 63 FLT1 -5 4 PDGFRA 
(D842V) 
-9 0 
AurB 2 23 FLT3 17 73 PDGFR-alpha(V5
61D) 
-10 -2 
AurC -5 4 Flt3(D835Y) -8 1 PhKg1 -2 12 
AXL 1 20 FLT4 4 33 PhKg2 -3 11 
BLK 27 86 FMS -2 13 PIM1 -4 6 
BMX 11 65 FRK 23 83 PIM2 56 97 
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BRSK1 -4 7 FYN 34 90 PIM3 0 19 
BRSK2 -1 14 GCK   52 93 PKA 10 60 
BTK 25 85 GSK3-alpha 8 53 PKC-alpha 27 86 
CaMK1a -5 4 GSK3b 9 58 PKCb2 -5 3 
CamK1d -2 12 Hck 5 46 PKC-beta1 18 73 
CAMK2 0 18 HER4 4 31 PKC-delta -3 9 
CaMK2a  3 29 HGK 6 49 PKC-epsilon 7 52 
CAMK4 -2 12 HIPK1 3 29 PKC-eta  8 55 
CaMKII_beta -6 2 HIPK2 -1 14 PKC-gamma 19 76 
CaMKII_gamm
a 
17 73 IGF1R 33 89 PKC-theta 23 83 
Casein kinase 
1g2 
-1 16 IKBKE (IKK 
epsilon) 
23 85 PKCz -2 12 
CDK1/Cycline 
B1 
-5 3 IKK-beta 60 98 PKD1 -1 16 
CDK2 5 43 INSR 32 87 PKD2 12 68 
CDK3 -5 3 IRAK4 21 83 PKD3 -4 5 
CDK5/p25 -4 4 ITK 5 45 PKG1-beta 0 18 
CHK1 12 66 JAK2 79 100 PKGa 2 21 
CHK2 17 71 VEGFR2 4 32 PRAK 10 63 
CK1d 0 18 KIT -7 1 PRKCI 
(PKC-iota ) 
1 20 
CK1-epsilon -1 16 KIT[T670I] -74 -45 PRKX 1 20 
CK1g3 
(CSNK1G3) 
-3 8 LCK 18 76 PYK2 29 86 
CK1-gamma1 -1 16 LOK 59 97 RET 49 92 
CLK2 1 20 LTK 18 76 Ret (V804L) -12 -5 
c-Raf -1 15 LYN 40 91 RET Y791F -9 -2 
CSNK1A1  -2 11 LYNB 50 92 ROCK1 15 69 
c-TAK1 -7 1 MAPKAPK2 9 59 ROCK2 25 86 
DAPK1 4 36 MAPKAPK3 7 52 ROS (ROS1) 54 94 
DCAMKL1 -4 6 MARK1 4 35 RSK1 3 28 
DCAMKL2 -6 2 MARK2 -3 9 RSK2 3 31 
DDR2 -6 2 MARK4  8 55 RSK3 9 56 
DYRK1a -5 3 MELK -2 13 RSK4 4 34 
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DYRK1B 5 40 Mer 32 87 SGK1 8 55 
DYRK3 0 20 MET 5 43 SGK2 6 47 
DYRK4 2 27 MET 
M1250T  
-10 -2 SGK3  11 64 
EGFR -3 9 MINK  16 70 SRC 39 90 
EGFR (ErbB1) 
T790M L858R  
-8 0 MNK1 
(MKNK1) 
16 70 SRM (SRMS) -4 6 
EGFR(T790M) -33 -34 MSK1 0 18 SYK 99 93 
EPHA1 11 66 MSK2  -5 3 TEC -5 2 
EPHA2 5 39 MST1 64 99 TRKC (NTRK3) 13 69 
EPHA3 7 49 MST1R 2 21 TSSK1 58 97 
EPHA4 2 22 MST2 20 78 TSSK2 20 81 
EPHA5 5 38 MST3 
(STK24) 
3 30 TXK -4 6 
EPHA8 5 42 NEK1 -4 5 TYRO3 7 53 
EPHB1 4 32 NEK2 -4 7 Yes 32 87 
EPHB2 5 43 NTRK2 
(TRKB) 
13 69 ZIPK (DAPK3) 72 99 
 
  
41 
 
Table 2. Biochemical IC50 values for TAS05567 and R406 against 5 kinases. 
Kinase 
ATP 
(µM) 
IC50 (nM) ATP 
(µM) 
IC50 (nM) 
TAS05567 R406 TAS05567 R406 
Syk 26 0.37 ± 0.029 13 ± 0.26 1000 1.5 ± 0.40 67 ± 14 
FLT3 94 10 < 0.30 1000 39 0.56 
JAK2 13 4.8 0.86 1000 160 25 
VEGFR2 74 600 9.8 1000 2600 42 
RET 7.5 29 2.8 1000 760 68 
       
Values are mean or mean ± SD for the IC50 values. 
Three independent experiments were performed to determine the IC50 values of Syk. 
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Table 3. Off-target receptor binding assays. 
Receptor TAS05567 
% inh at 10 
µM 
Receptor TAS05567 
% inh at 10 
µM 
Receptor TAS05567 
% inh at 10 
µM 
Adenosine A1 75 Epidermal 
Growth 
Factor  
-19 Neuropeptide Y Y2 4 
Adenosine A2A 2 Estrogen 
ERalpha 
1 Nicotinic 
Acetylcholine 
-10 
Adenosine A3 5 Transporter, 
GABA 
15 Nicotinic 
Acetylcholine 
Alpha1, 
Bungarotoxin 
0 
Adrenergic alpha1A 12 GABAA, 
Muscimol, 
Central 
-4 Opiate delta1 (OP1, 
DOP) 
0 
Adrenergic alpha1B 7 GABAA, 
Flunitrazepa
m, Central 
24 Opiate kappa (OP2, 
KOP) 
11 
Adrenergic alpha1D 10 GABAB1A -3 Opiate mu (OP3, 
MOP) 
9 
Adrenergic alpha2A -7 Glucocorticoi
d 
9 Phorbol Ester -9 
Adrenergic beta1 -5 Glutamate, 
Kainate 
8 Platelet Activating 
Factor (PAF) 
-10 
Adrenergic beta2 15 Glutamate, 
NMDA, 
Agonism 
3 Potassium Channel 
[KATP] 
-3 
Transporter, Norepinephrine 12 Glutamate, 
NMDA, 
Glycine 
4 Potassium Channel 
hERG 
26 
Bradykinin B1 15 Glutamate, 
NMDA, 
Phencyclidine 
-3 Prostanoid EP4 -2 
Bradykinin B2 -3 Histamine H1 -7 Purinergic P2X 5 
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Calcium Channel L-Type, 
Benzothiazepine 
15 Histamine H2 4 Purinergic P2Y 0 
Calcium Channel L-Type, 
Dihydropyridine 
28 Histamine H3 8 Rolipram 34 
Calcium Channel N-Type 5 Imidazoline 
I2, Central 
12 Serotonin 
(5-Hydroxytryptamin
e) 5-HT1A 
-8 
Cannabinoid CB1 6 Interleukin 
IL-1 
-10 Serotonin 
(5-Hydroxytryptamin
e) 5-HT2B 
-9 
Dopamine D1 -1 Leukotriene, 
Cysteinyl 
CysLT1 
11 Serotonin 
(5-Hydroxytryptamin
e) 5-HT3 
-13 
Dopamine D2S -5 Melatonin 
MT1 
4 Transporter, 
Serotonin 
(5-Hydroxytryptamin
e) (SERT) 
-4 
Dopamine D3 3 Muscarinic 
M1 
0 Sigma1 -2 
Dopamine D4.2 -1 Muscarinic 
M2 
-1 Sodium Channel, Site 
2 
30 
Transporter, Dopamine 24 Muscarinic 
M3 
-7 Androgen 
(Testosterone) AR 
-8 
Endothelin ETA 11 Tachykinin 
NK1 
6 Thyroid Hormone 3 
Endothelin ETB 0 Neuropeptide 
Y Y1 
-1   
Off-target effects of 10 µM TAS05567 were assessed using the LeadPrifilingScreen 
commercial assay. Results that show an inhibition or stimulation >50% are considered 
to represent significant effects on the test compound. 
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1.3.2 TAS05567 Inhibits BCR-dependent Signaling and FcγR-dependent Functions 
As Syk is a key mediator of BCR activation in B cells, we evaluated the effectiveness 
of TAS05567 in blocking the BCR-dependent signaling cascade. When Ramos cells 
(human B lymphoma cells) were pretreated with TAS05567 prior to BCR cross-linking 
by exposure to anti-IgM, there was marked inhibition of the phosphorylation of BLNK, 
an adaptor protein phosphorylated by activated Syk (Figure 2A). The IC50 of 
TAS05567 for suppressing induction of BLNK phosphorylation by anti-IgM was 1.8 
nM, which was lower than that of R406. We also examined whether TAS05567 
inhibited other downstream signaling molecules, including PLCγ2 (IC50, 23 nM) and 
Erk1/2 (IC50, 9.8 nM), after stimulation of Ramos cells with anti-IgM (Figure 2B, C). 
TAS05567 showed stronger inhibition of these molecules in the BCR-dependent 
signaling cascade than R406.  
Syk reportedly plays a central role in FcγR-mediated production of proinflammatory 
cytokines by monocytes and macrophages [62]. Therefore, we evaluated the inhibitory 
effect of TAS05567 on IgG-induced TNF-α release by THP-1 cells. TAS05567 showed 
concentration-dependent inhibition of TNF-α production by THP-1 cells stimulated with 
IgG (Figure 3A). In contrast, TAS05567 had minimal effect on LPS-induced production 
of TNF-α by these cells, as already reported [63]. These finding suggest that TAS05567 
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specifically inhibits the FcγR-mediated pathway. Basically, cell-based assays in the 
present study were carried out under culture conditions with FBS. Hence, we also 
performed IgG-induced TNF-α production assay using medium containing 10% human 
serum albumin to give our compound relevance as a potential treatment for 
inflammatory diseases in humans. The IC50 value of TAS05567 in human settings was 
46 nM, which has been almost the same result when using 10% FBS containing medium 
(Figure 3B). Clearance of antibody-bound platelets in patients with ITP is mediated by 
phagocytes activated by antibody binding to FcγR [21]. We therefore assessed the 
effects of TAS05567 on the IgG-FcγR mediated phagocytic acidity in RAW264.7 cells. 
As shown in Figure 3C, treatment of RAW264.7 cells with TAS05567 resulted in 
inhibition of FcγR-mediated phagocytosis of IgG-opsonized latex beads.  
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Figure 2. Effects of TAS05567 and R406 on BCR-dependent signaling pathways.  
Ramos cells were activated with anti-human IgM F(ab’)2 fragments for 10 min in the 
presence of increasing concentrations of TAS05567 or R406. The phosphorylation 
levels of BLNK (A), PLCγ2 (B), and Erk1/2 (C) were analyzed by flow cytometry. 
Values are presented as percent of mean fluorescence intensity relative to vehicle 
control cells (100%) and non-stimulated control cells (0%). Data are presented as mean 
± SD. 
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Figure 3. FcγR-mediatd functional activity of TAS05567 in cell-based assays.  
(A) THP-1 cells were cultured in RPMI-1640 medium with 10% FBS, and then were 
seeded in a microwell plate coated with purified human IgG and incubated for 4 h in the 
presence of increasing concentrations of TAS05567 (circles). THP-1 cells were seeded 
in an uncoated plate and then stimulated with lipopolysaccharide (LPS) for 24 h in the 
presence of increasing concentrations of TAS05567 (squares). The level of TNF-α in the 
culture supernatant was measured by ELISA. (B) THP-1 cells were cultured in 
RPMI-1640 medium with 10% HSA, and then were seeded in a microwell plate coated 
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with purified human IgG and incubated for 4 h in the presence of increasing 
concentrations of TAS05567. The level of TNF-α in the culture supernatant was 
measured by ELISA. (C) RAW264.7 cells were pretreated with TAS05567 or 
cytochalasin D (Cy D) for 1 h, followed by incubation with latex beads coated with 
FITC-labeled IgG (1:500) for 4 h. The cells were collected and analyzed by flow 
cytometry. Data are presented as mean ± SD. 
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1.3.3 TAS05567 inhibits IL-1β secretion by NLRP3 inflammasome activation 
Recently, Syk has been reported to positively regulate NLRP3 inflammasome 
activation and promote IL-1β secretion in macrophages and dendritic cells [64], even 
though NLRP3 inflammasome activation may not be regulated by FcR-dependent 
signaling pathway. Since aberrant inflammasome activation has been associated with a 
wide variety of inflammatory diseases [65], we investigated the effect of TAS05567 on 
IL-1β secretion induced by Alum, one of the NLRP3 ligands, from PMA-treated 
macrophage-like THP-1 cells. TAS05567 suppressed the IL-1β secretion from the 
LPS-primed cells in a concentration-dependent manner (Figure 4).  
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Figure 4. TAS05567 blocks IL-1β production by stimulation with Alum.  
THP-1 cells were differentiated with 0.2 µM PMA for 3 days and seeded in a 96-well 
plate in RPMI-1640 containing 10% FBS overnight. On the next day, the cells were 
primed with LPS (1 µg/ml) for 3 h and then pretreated with TAS05567 for another 1h. 
The cells were stimulated with Alum Adjuvant (30 µg/ml) for 9 h. The levels of IL-1β in 
the culture supernatant were measured by ELISA. Data are presented as mean ± SD. 
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1.3.4 TAS05567 Suppresses Development of TRAP-positive Multinucleated Cells 
In addition to its crucial role in inflammation, Syk contributes directly to bone 
resorption in RA via its kinase activity–mediated regulation of RANK signaling 
pathway that is essential for differentiation and activation of osteoclasts [39]. Therefore, 
we explored the effect of TAS05567 on osteoclast differentiation using human 
osteoclast precursor cells. After precursor cells were cultured with the indicated 
concentrations of TAS05567 for 4 days in the presence of M-CSF and RANKL, 
development of TRAP-positive multinucleated mature osteoclasts was assessed on day 
5 (Figure 5A). TAS05567 inhibited the formation of mature osteoclasts in a 
concentration-dependent manner, and osteoclast differentiation was completely 
suppressed at 30 nM (Figure 5B). 
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Figure 5. TAS05567 inhibits osteoclastogenesis in a concentration-dependent manner. 
(A) Representative images of TRAP staining showing M-CSF and RANKL-mediated 
mature osteoclast differentiation from human osteoclast precursors. Negative control 
and positive control wells are labeled as (−) RANKL (upper left) and (+) RANKL 
(upper right), respectively. TAS05567 concentration is labeled on the upper portion of 
each image. (B) The total number of TRAP-positive osteoclasts per well was 
determined by manual counting. Data are presented as mean ± SD. 
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1.2.5 TAS05567 Inhibits IgD-induced BLNK Phosphorylation in Mouse and Rat 
Whole Blood 
As plasma protein binding by drugs has a marked influence on drug activity in vivo, 
we performed whole-blood assays using samples from mice and rats to assess inhibition 
of BCR-dependent signal transduction as a surrogate pharmacodynamic marker for 
efficacy in animal models. After peripheral blood samples collected from mice or rats 
were pretreated with TAS05567 at the indicated concentrations, BLNK phosphorylation 
was assessed following stimulation with anti-IgD. TAS05567 inhibited anti-IgD–
induced BLNK phosphorylation in the peripheral blood B cells of mice and rats in a 
concentration-dependent manner (Table 4), with estimated IC50 values of 
approximately 0.2 µM and 0.3 µM, respectively. We also determined the plasma protein 
binding of TAS05567 using mouse, rat, and human plasma. The mean unbound fraction 
of TAS05567 in plasma was 15.4% in mouse, 18.3% in rat, and 21.9% in human (Table 
5), and therefore the plasma protein binding of TAS05567 was almost the same level 
between rodents and human. 
By integrating the whole-blood assay results with single-dose pharmacokinetic data, 
we calculated the estimated duration of Syk inhibition by TAS05567 in vivo. In mice, 
the plasma TAS05567 concentration was 0.47 µM at 6 h after administration of 10 
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mg/kg, indicating that it was above the IC50 in the mouse whole-blood assay for more 
than 6 h (Figure 6A). When rats were administered TAS05567 at doses of 10 mg/kg or 
25 mg/kg, the plasma concentration remained above the IC50 in the rat whole-blood 
assay for approximately 8 h and 18 h, respectively (Figure 6B). 
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Figure 6. Oral pharmacokinetics of TAS05567 in mice and rats.  
(A) Male BALB/c mice were dosed orally with 10 mg/kg of TAS05567, and plasma 
samples were collected at 0.5, 1, 2, 4, and 6 h after administration. The concentration of 
the compound in plasma samples was analyzed as described in the Materials and 
Methods section. Data are expressed as mean ± SEM (n=3). Dashed line shows the 
IC50 value determined against BCR-mediated BLNK phosphorylation in B cells in 
mouse whole blood. (B) Male Sprague-Dawley rats were dosed orally with 10 mg/kg or 
25 mg/kg, and plasma samples were collected at 1, 2, 4, 8, and 24 h after administration. 
The concentration of the compound in plasma samples was analyzed as described in the 
Materials and Methods section. Data are expressed as the mean (n=2). Dashed line 
shows the IC50 value determined against BCR-mediated BLNK phosphorylation in B 
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cells in rat whole blood. 
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Table 4. Effects of TAS05567 on BLNK phosphorylation in mouse or rat whole blood 
evoked by anti-IgD. 
Animal Cell Type 
TAS05567 (µM) 
0.1 0.3 1 3 
Mouse CD45R / B220+ 27% 67% 95% NA 
Rat CD45RA+ NA 49% 82% 104% 
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Table 5. Plasma protein binding of TAS05567. 
Species 
Unbound fraction (%) 
TAS05567 
Mouse 15.4 ± 0.5 
Rat 18.3 ± 1.1 
Human 21.9 ± 0.1 
 
TAS05567 was tested at a final concentration of 1 µM in mouse, rat, and human plasma. 
An aliquot of plasma containing TAS05567 was in the well of equilibrium dialysis 
device. The plate containing plasma and buffer was equilibrated at 37°C for 6 h, with 
constant shaking at 80 rpm on an orbital shaker. Samples were collected and 
precipitated using organic solvents. All samples were centrifuged at 850g for 5 min at 
4°C, and then were analyzed by liquid chromatography–tandem mass spectrometry. 
Data are presented as mean ± SD (n = 3). 
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1.3.6 TAS05567 suppresses progression in mouse models of CAIA and CIA 
To investigate the potential therapeutic value of TAS05567 for RA, we evaluated its 
effects in representative rodent models of arthritis. CAIA (type II collagen 
antibody-induced arthritis) is mainly mediated by innate immunity and FcγR-bearing 
cells are particularly associated with antibody-mediated joint inflammation [65]. When 
administered orally at doses of 10 and 30 mg/kg/day for 9 days starting from day 0 
before injection of a monoclonal antibody cocktail, TAS05567 inhibited the 
development of arthritis based on clinical scores, with complete inhibition at 30 mg/kg 
(>90% inhibition; Figure 7A). In addition, serum MMP-3 level was significantly lower 
in both the10 mg/kg and 30 mg/kg TAS05567 groups than in the vehicle group (Figure 
7B).  
We also assessed the effect of TAS05567 in a mouse CIA model because this arthritis 
model has a similar pathogenetic mechanism to human RA due to involvement of 
several immune cells, including T cells, B cells, and macrophages [66]. TAS05567 was 
administered prophylactically to the mice at 3 mg/kg or 10 mg/kg/day for 14 days 
starting from day 0 before the second immunization. When administered at 10 mg/kg, 
TAS05567 achieved statistically significant improvement of arthritis symptoms 
compared with the vehicle group (Figure 8A). In addition, the serum level of anti-type 
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II collagen antibody was significantly reduced at the end of the study in the 
TAS05567-treated mice (Figure 8B), indicating that suppression of antibody production 
may have contributed to the improvement of arthritis. 
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Figure 7. TAS05567 suppresses inflammation in the mouse CAIA model.  
(A) Treatment was started from day 0 at the same time as injection of anti-type II 
collagen antibody and continued for 9 days. Clinical scores were evaluated every 3 days. 
Groups included naïve, vehicle, prednisolone (3 mg/kg/day), and TAS05567 (10 and 30 
mg/kg/day). (B) Serum levels of MMP-3 were determined by ELISA after 9 days of 
treatment with TAS05567 or vehicle. Data are presented as mean ± SEM (n=10 per 
group). * P<0.05 and ** P<0.01 compared with the vehicle group. 
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Figure 8. TAS05567 inhibits inflammation and autoantibody production in the mouse 
CIA model. 
(A) Treatment was started from day 0 at the same time as a boost immunization and 
continued for 14 days. Clinical scores were evaluated twice a week. Groups were given 
vehicle and TAS05567 (3 and 10 mg/kg/day). Data are presented as mean ± SEM for n 
= 10 per group. (B) Serum levels of anti-bovine type II collagen IgG after 14 days of 
treatment with TAS05567 (n = 7) or vehicle (n = 10) were detected by ELISA. Data are 
presented as mean ± SEM. ** p<0.01 compared with vehicle group. 
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1.3.7 TAS05567 improves symptoms in a rat model of established CIA 
To further explore the therapeutic potential of TAS05567, we tested rats with CIA 
using a therapeutic dosing regimen. Rats with a significant increase in foot pad volume 
(indicating paw swelling) were randomly assigned to the vehicle, TAS05567, or R406 
groups. Although there was no significant improvement in the 4 mg/kg TAS05567 
group, treatment with TAS05567 at doses of 10 mg/kg and 25 mg/kg resulted in 
significant reduction of joint inflammation (Table 6). In addition, histopathologic 
examination of the left and right hind paws revealed significant reduction of 
inflammatory cell infiltration into the synovium and pannus formation in both the 10 
mg/kg and 25 mg/kg TAS05567 groups (Figure 9A, B). At these doses, TAS05567 also 
markedly ameliorated damage to cartilage and bone (Figure 9A, B). R406 treatment also 
significantly reduced the severity of CIA, markedly abrogating joint swelling as well as 
cartilage destruction (Table 7 and Figure 11B). Moreover, we evaluated the serum level 
of COMP, an extracellular matrix glycoprotein associated with disease activity and 
cartilage damage in RA patients [67]. TAS05567 reduced serum COMP levels in a 
dose-dependent manner (Figure 9C). R406 also significantly inhibited the production of 
COMP. Finally, we monitored changes in body weight during treatment as an index of 
general toxicity and assessed red blood cell count and hemoglobin levels because 
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anemia was observed in some patients during clinical trials of drugs with JAK2 
inhibition [68]. As shown in Figure 10A, the change in body weight was similar 
between TAS05567- or R406-treated CIA rats and naïve rats. Body weight was higher 
in TAS05567- or R406-treated rats due to amelioration of systemic inflammation in 
comparison with vehicle-treated rats. In addition, TAS05567 did not significantly 
reduce the red blood cell count or hemoglobin level in any dose group compared with 
the vehicle-treated controls (Figure 10B, C). However, both red blood cell count and 
hemoglobin level in the R406 group were significantly lower than in the vehicle group.  
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Table 6. Therapeutic effects of TAS05567 or R406 on antiarthritic activity in 
collagen-induced arthritis in rat. 
Group 
Hind paw volume (ml) 
Day 1 Day 8 Day 14 
Naive 2.31 ± 0.03 2.31 ± 0.05 2.28 ± 0.05 
Vehicle 2.56 ± 0.07a 2.88 ± 0.12 2.92 ± 0.13 
TAS05567 (4 mg/kg) 2.55 ± 0.08 2.63 ± 0.08 2.66 ± 0.12 
TAS05567 (10 mg/kg) 2.60 ± 0.10 2.41 ± 0.04b 2.34 ± 0.03c 
TAS05567 (25 mg/kg) 2.54 ± 0.07 2.34 ± 0.04c 2.33 ± 0.03c 
R406 (30 mg/kg) 2.58 ± 0.09 2.41 ± 0.08 c 2.49 ± 0.10 b 
Prednisolone (3 mg/kg) 2.54 ± 0.06 2.44 ± 0.03c 2.47 ± 0.05c 
    
Data are presented as mean ± SEM. n=6 rats in the naïve group; n=9 rats each in the 
vehicle and treatment groups. a P<0.01 compared with the naïve group. b P<0.05 
compared with the vehicle group. c P<0.01 compared with the vehicle group. 
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Figure 9. TAS05567 improves disease severity in a dose-dependent manner in the 
established rat CIA model. 
(A) Both hind paws from each rat after 14 days of treatment with vehicle, TAS05567, 
R406, or prednisolone were processed for histologic evaluation of joint inflammation, 
pannus formation, cartilage damage, and bone damage. Histologic changes for each 
parameter were scored (range, 0-8). (B) Representative photomicrographs of 
hematoxylin-eosin staining are shown (original magnification ×40). (C) Serum levels of 
COMP after 14 days of treatment in naïve, vehicle, prednisolone, R406, and TAS05567 
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groups as determined by ELISA. Data are presented as mean ± SEM. n=6 rats in the 
naïve group; n=9 rats each in the vehicle and treatment groups. * P<0.05 and ** P<0.01 
compared with the vehicle group. 
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Figure 10. TAS05667 does not affect body weight, red blood cell count, or hemoglobin 
level in the established rat CIA model. (A) CIA rats with clinical sings of paw swelling 
were randomized at day 1. Treatment was started from day 1 and continued for 14 days. 
Changes in body weight of the rats were monitored every day. Body weight changes 
(0% at day 1) for each group are presented as average values. Peripheral blood samples 
from were obtained from the rats and analyzed for changes in red blood cell count (B) 
and hemoglobin level (C). Data are presented as mean ± SEM. n=6 rats in the naïve 
group; n=9 rats each in the vehicle and treatment groups. * P<0.05 and ** P<0.01 
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compared with the vehicle group. 
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1.3.8 TAS05567 Ameliorates Thrombocytopenia in a Mouse Model of ITP 
ITP is an autoantibody-mediated disorder in which IgG binds to platelets and causes 
their accelerated clearance via FcγR expressed on macrophages [21]. TAS05567 
inhibited FcγR-dependent phagocytosis in macrophages (Figure 3C). Accordingly, we 
examined whether TAS05567 could attenuate platelet count decreases in mice with 
thrombocytopenia induced by administration of an antiplatelet antibody. In mice 
injected with an anti-CD41 antibody, the platelet count decreased by more than 50% 
compared with sham mice, whereas the platelet count in IVIg-treated mice was 
significantly higher than that of vehicle-treated mice (Figure 11). In this model, 
TAS05567 provided significant protection against anti-CD41 antibody–induced 
thrombocytopenia in a dose-dependent manner and completely prevented 
thrombocytopenia when administered at 100 mg/kg (Figure 11). Some signs of toxicity, 
such as body weight loss and lower locomotor activity, were not observed during the 
treatment period (data not shown). The platelet count in R406-treated mice was also 
significantly higher than that of vehicle-treated mice, but this drug only partially 
prevented thrombocytopenia even at 100 mg/kg (Figure 11).  
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Figure 11. TAS05567 protects mice from anti-platelet antibody–induced 
thrombocytopenia.  
Mice were treated with TAS05567 (10, 30, 100 mg/kg) or R406 (100 mg/kg) on days 1 
and 2. For the IVIg group, mice were intravenously injected with 1 g/kg IVIg once on 
day 1 only. On day 2, mice were intravenously injected with anti-CD41 antibody. 
Platelet counts were evaluated 24 h later. Data are presented as mean ± SEM (n=5 or 6 
per group). * P<0.05 and ** P<0.01 compared with the vehicle group. 
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1.3 Discussion 
In this chapter, we determined the pharmacological profile of a novel selective Syk 
inhibitor, TAS05567, which potently inhibited BCR signaling as well as 
FcγR-dependent cellular functions. TAS05567 also inhibited osteoclast differentiation 
and blocked IL-1β release triggered by NLRP3 inflammasome activation. After oral 
administration, TAS05567 was well tolerated and ameliorated symptoms in animal 
models of RA and ITP, which are both humoral immune-mediated autoimmune 
diseases. 
Our biochemical assays revealed that R406 showed inhibitory activity against several 
protein kinases, including VEGFR2 and JAK2, which are associated with the potential 
risk of hypertension and anemia [46, 47]. Among several inhibitors of the kinase 
activity of Syk under development, Fostamatinib has demonstrated effectiveness for ITP 
in Phase III trials [55], but hypertension was more frequent in the Fostamatinib group 
than in the placebo group during clinical trials for RA [56]. In addition, anemia was 
observed in the patients treated with Tofacitinib and Baricitinib owing to inhibition of 
JAK2 kinase activity [69, 70]. Compared with R406, TAS05567 not only showed lower 
activity against theses kinases, but also displayed more potent inhibition of Syk activity 
(Figure 1, Table 1, and Table 2). Regarding Syk and the selected 4 kinases, including 
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VGFR2 and JAK2, we also performed the enzymatic assays at 1 mM ATP to 
approximate cellular concentrations. In this condition, TAS05567 inhibited Syk activity 
with IC50 of 1.5 nM, but much less activity against the 4 kinases, demonstrating that 
TAS05567 has highly selective inhibitory activity against Syk kinase at the cellular 
level. Indeed, in the rat model of established CIA, body weight and hematology 
parameters for anemia were not affected by 2 weeks of treatment with TAS05567 
(Figure 10A, B, and C), suggesting that it is well tolerated. In addition to assessing 
selectivity for protein kinases, we performed cellular assays to obtain data about 
targeting of the immune system by TAS05567. Interestingly, although TAS05567 
markedly reduced FcγR-mediated proinflammatory cytokine, TAS05567 had little effect 
on the response to TLR4 stimulation (Figure 3A). Innate immune responses mediated 
through TLR4, which is mainly expressed on monocytes and neutrophils, are associated 
with host defenses against microbial infection, particularly gram-negative bacteria [71]. 
Therefore, this feature of TAS05567 could be an advantage for treating patients with 
autoimmune diseases such as RA because an increased risk of infection has been one of 
the major issues with conventional therapies [6, 8]. To delineate the toxicity profile of 
TAS05567 in detail, further toxicity studies in rodents or non-rodent species will be 
required.  
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In the joints of patients with RA, autoantibodies form ICs that interact with FcRs 
expressed on synovial immune cells to induce production of proinflammatory cytokines, 
resulting in disease progression [72]. Similar to human RA, anti-type II collagen 
antibodies form ICs that activate FcγRs on macrophages and monocytes in animal 
models, causing synovitis in CAIA and CIA [65, 73]. Consistent with the inhibitory 
effect of TAS05567 on FcγR-mediated immune responses in vitro, treatment with this 
drug dose-dependently suppressed paw swelling in both rodent models (Figure 7A, 8A, 
and Table 6). Of note, in pharmacokinetic studies and whole-blood assays, the robust 
effect of TAS05567 in these arthritis models was achieved without continuous inhibition 
of the target (Figure 6), which is consistent with a previous report [74]. Therefore, 
TAS05567 may provide significant benefit for patients with RA at doses that partially 
suppress Syk activity, thus mitigating the toxic effects associated with complete genetic 
deletion of Syk. In the present study, it is interesting that TAS05567-treated CIA mice 
also showed significant reduction of anti-type II collagen IgG production (Figure 8B). 
Syk has been reported to be involved in antibody production via TLR9 signaling and is 
required for differentiation of plasma cells in the presence of antigens [75]. Accordingly, 
our data suggest that direct inhibition of autoantibody production by a Syk inhibitor 
may contribute to improvement of arthritis symptoms, in addition to blockade of 
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FcR-mediated signaling in effector cells.  
This study demonstrated that TAS05567 strongly suppresses damage to bone in a rat 
model of established CIA (Figure 9A, B). Syk is recruited and phosphorylated as a 
result of the RANKL-RANK interaction, after which it induces activation of c-Fos and 
nuclear factor of activated T cells cytoplasmic 1, leading to differentiation of functional 
osteoclasts [76]. Consistent with the findings obtained in Syk-deficient cells [34], in the 
present study, TAS05567 blocked the differentiation of mature osteoclasts from 
immature cells in the presence of RANKL (Figure 5). In a recent clinical trial, an 
anti-RANKL antibody (Denosumab) achieved clinically meaningful and significant 
reduction of bone erosion in RA patients, suggesting that drugs which target the 
RANKL pathway could become novel options for RA patients with risk factors for joint 
destruction [77]. However, Denosumab failed to improve joint space narrowing, which 
reflects cartilage damage [77]. In the present study, there was histological improvement 
of the ankle joints in TAS05567-treated CIA rats and the serum COMP concentration 
decreased to almost the same levels as in naive rats (Figure 9C). Several studies have 
shown that elevation of the serum COMP level reflects joint damage, particularly 
cartilage degradation [67, 78]. Furthermore, TAS05567 reduced the serum MMP-3 level 
in CAIA mice in the present study (Figure 7B). MMP-3 plays a pivotal role in the 
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degradation of cartilage components, and this enzyme is produced when synovial cells 
are stimulated by proinflammatory cytokines such as TNF-α and interleukin-1β [79]. 
Indeed, it was reported that R406 blocks TNF-α–induced MMP-3 production in 
fibroblast-like synoviocytes from RA patients by suppressing Syk pathway activation 
[80]. Thus, improvement of cartilage damage in our rat CIA model may have been 
associated with suppression of MMP-3 production by TAS05567, although the serum 
MMP-3 level was not determined in this study. Taken together, these findings suggest 
that TAS05567 would be useful for alleviating both progressive bone erosion and 
cartilage damage in RA. 
In addition to its potential usefulness for treating RA, TAS05567 inhibited 
FcγR-dependent phagocytosis in macrophages (Figure 3C) and exhibited significant 
efficacy in a representative animal model of ITP at the same dosage used in the mouse 
arthritis model (Figure 11). Lu and colleagues reported that decreasing Syk expression 
in macrophages by transfection with Syk-specific siRNA attenuates antibody-mediated 
phagocytosis, a finding that is consistent with our data [81]. Of note, treatment with 
TAS05567 at 100 mg/kg completely prevented the induction of thrombocytopenia by 
injection of anti-CD41 antibody in the present study. Fostamatinib also showed efficacy 
in a similar model of ITP, but it only partially prevented thrombocytopenia even at 100 
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mg/kg in this study (Figure 11). Fostamatinib was reported to be effective against 
refractory ITP in clinical trials, but not all patients responded to it [45]. Considering the 
balance between efficacy and safety, 100 mg/kg may be too high a dose of TAS05567, 
even though no toxicity was observed during the treatment period in our experiments. 
However, TAS05567 has much higher selectivity for the target enzyme than 
Fostamatinib, suggesting that it would be better tolerated and can be used at higher 
doses without causing off-target side effects. Taken together, these results suggest that 
TAS05567 could become a novel option for the treatment of a broad range of ITP 
patients, including those refractory to conventional therapies.  
We also demonstrated that TAS05567 inhibited secretion of IL-1β by 
macrophage-like cells stimulated with alum (Figure 4). Recent research has shown that 
Syk mediates NLPR3 stimulus-induced activation of caspase-1 in ICs-independent 
manner and consequently inhibits secretion of IL-1β and IL-18 via the association with 
NLRP3 and adaptor protein ASC [64]. The NLRP3 inflammasome has been reported to 
be involved in the pathogenesis of several inflammatory diseases, including RA, 
inflammatory bowel disease, gout, cryopyrin-associated periodic syndromes (CAPS), 
and Alzheimer's disease [82]. Indeed, IL-1 blockers have been approved by the U.S. 
Food and Drug Administration to treat RA and CAPS [83]. Consequently, besides being 
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a possible new therapeutic option for specific autoimmune diseases, TAS05567 may be 
an attractive candidate for a wide range of inflammatory disorders related to the NLRP3 
inflammasome. Therefore, we need to investigate the detailed molecular mechanisms by 
which TAS05567 modulates NLRP3 inflammasome responses using cellular assays to 
examine whether this drug could be an option for treating diseases caused by 
inflammasome overactivation. 
Our data support the possibility that TAS05567 could become a novel treatment for 
diseases such as RA, ITP, and other inflammatory disorders related to abnormal 
activation of Syk. 
  
79 
 
Chapter 2 
Therapeutic effects of TAS05567 on allergic diseases as well as B-cell malignancies 
using preclinical animal models 
 
2.1 Introduction 
Type 1 allergic diseases, such as allergic rhinitis, atopic dermatitis, asthma, and 
allergic anaphylaxis, are called the epidemics of the 21st century [29, 84]. Allergic 
symptoms range from local reactions of the mucosa to generalized symptoms in the skin, 
airways, gastrointestinal tract, and circulation system, and it is estimated that up to 25% 
of the population may be affected by them. [85, 86]. The role of antigen-specific IgE in 
type 1 allergic diseases has been revealed, with antigen-mediated IgE cross-linking 
inducing the degranulation of mast cells/basophils [28]. The IgE-primed these cells 
release granules and several chemical mediators, including histamine, leukotrienes, and 
cytokines, which cause the characteristic allergic reactions, such as hives, wheezing,  
abdominal symptoms, and even anaphylaxis diseases [30]. Of note, FcεRI or Syk 
deletion in mice reduces allergic responses in animal models of allergy [31, 40]. From 
these findings, Syk is implicated as a key regulator of the disease progression in patients 
with type 1 allergic diseases, and therefore, inhibitors targeting Syk kinase may be 
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promising and attractive therapeutic option for the treatment of these diseases.  
BCR signaling cascades are activated and required for cell survival in some B-cell 
lymphoma, such as DLBCL [41]. DLBCL is the most common subtype of non-Hodgkin 
lymphoma (NHL), and the estimated incidence is ∼7 per 1000,000 person-years in 
Western countries [87, 88, 89]. The standard of care for initial treatment of DLBCL is 
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, which achieves 
a cure in many patients [90]. However, despite potentially curable, ∼40% of patients 
with DLBCL were died of relapse or refractory disease [43, 91]. Syk protein is activated 
in an approximately half of primary human DLBCL tissues by a tissue microarray 
analysis, suggesting that Syk kinase holds promise as a therapeutic target for DLBCL 
[42]. Indeed, Syk inhibitors, such as GS-9973, have also been developed for the therapy 
of the lymphoma including DLBCL [48, 92].  
In this chapter, we examined the therapeutic potential of TAS05567 against type 1 
allergic diseases and DLBCL tumors using in vitro assays as well as preclinical animal 
models. In in vitro experiments, we investigated whether not only TAS05567 could 
block antigen-induced calcium flux and histamine release in IgE-sensitized basophilic 
cells, but also inhibit cell cycle progression as well as proliferation of DLBCL cells 
through Syk-mediated signaling cascades. Moreover, we investigated whether 
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TAS05567 could suppress the ear swelling provoked by antigen as an index of type 1 
allergic reaction in TNP-specific IgE transgenic mice. Finally, the in vivo antitumor 
activity of TAS05567 was evaluated in SCID mice bearing SU-DHL-10, one of the 
DLBCL cell lines, xenograft. 
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2.2 Materials and Methods 
2.2.1 FcεRI-mediated Calcium Flux and Histamine-release Assay 
The intracellular calcium level was determined using a FLIPR® Calcium 6 Assay kit 
(Molecular Devices, Sunnyvale, CA, USA). RBL-2H3 cells (ATCC CRL-2256) were 
seeded overnight at 5 × 104 cells/well in a 96-well clear-bottomed plate with black walls 
in Minimum Essential Media containing 15% FBS. After washing with serum-free 
MEM, the cells were sensitized by incubation for 1 h at 37°C with mouse 
anti-2,4-dinitrophenyl (DNP) -IgE (0.3 µg/ml, Sigma-Aldrich), followed by incubation 
with FLIPR® Calcium 6 Assay kit dye and TAS05567 for 2 h at 37°C. DNP–bovine 
serum albumin (BSA) (0.1 µg/ml, LSL, Tokyo, Japan) was added and fluorescence 
(relative fluorescence units: RFUs) was detected every 30 s at an excitation wavelength 
of 485 nm and an emission wavelength of 525 nm using a Flex Station II (Molecular 
Devices). ΔRFU was calculated by subtracting the value at initiation of measurement. 
For the histamine-release assay, RBL-2H3 cells were seeded overnight in a 96-well 
plate (2 × 104 cells/well). After washing, the cells were sensitized by incubation with 
mouse anti-DNP-IgE (0.3 µg/ml) for 1 h at 37°C. The sensitized cells were then 
pretreated with TAS05567 for 1 h, followed by stimulation with DNP-BSA (0.1 µg/ml) 
for 15 min at 37°C and measurement of histamine in the supernatant using a histamine 
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EIA kit (Medical & Biological Laboratories, Nagoya, Japan). 
2.2.2 Detection of Syk and BLNK Phosphorylation (SU-DHL-10 cells) 
SU-DLH-10 (ATCC CRL-2963) was purchased from the American Type Culture 
Collection and maintained in RPMI-1640 medium (Sigma-Aldrich) containing 10% 
FBS. SU-DHL-10 cells (8 × 104 cells/100 µl) were pretreated with test compounds, 
followed by stimulation with goat F(ab’)2 anti-human IgG (5 µg/ml; Southern Biotech) 
for 10 min at 37°C. For the detection of Syk phosphorylation, the cells were lysed in 
lysis buffer (EMD Millipore, Burlington, Germany) supplemented with a mixture of 
protease inhibitors. The level of Syk phosphorylation (Y525/Y526) in the cell lysate 
was determined by enzyme-linked immunosorbent assay (ELISA) (Cell Signaling 
Technology, Danvers, MA, USA). For the detection of BLNK phosphorylation, the cells 
were fixed after the stimulation with anti-human IgG. Then, the cells were washed in 
staining buffer (FBS) (BD Biosciences) and incubated for 1 h at RT in the same buffer 
containing Alexa Fluor 488–labeled mouse anti-BLNK (pY84) (clone J117-1278) (BD 
Biosciences). Subsequently, the cells were resuspended in staining buffer (FBS). 
Phosphorylation of BLNK induced by anti-IgM antibody was quantified using a Guava® 
easyCyte flow cytometry systems (EMD Millipore). 
2.2.3 Cell Viability Assay 
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SU-DHL-5 (ATCC CRL-2958), SU-DHL-6 (ATCC CRL-2959), SU-DHL-10 (ATCC 
CRL-2963), and Pfeiffer (ATCC CRL-2632) were purchased from the American Type 
Culture Collection. Each cell line was seeded in 96-well plates at a density of between 3 
× 103 and 8 × 103, cultured in RPMI 1640 containing 10% FBS for 24 h at 37ºC, and 
then incubated with TAS05567 for another 72 h in the same medium. Cell viability was 
analyzed with CellTiter-Glo® luminescent cell viability assay kit (Promega KK, Tokyo, 
Japan). After cultivation for 72 h, an equal volume of CellTiter-Glo® reagent was added, 
the plates were shaken and luminescence was measured using a microplate 
luminometer.  
2.2.4 Cell Cycle Analysis 
SU-DHL-10 cells were exposed to TAS05567 for 24 h or 72h. The cells were 
collected, washed with PBS and stained for cell cycle analysis using Cycletest™ Plus 
DNA Reagent Kit (BD Biosciences). The stained cells were analyzed by a flow 
cytometer (BD Biosciences). The proportion of cells in SubG1, G1, S, and G2/M phases 
was represented as DNA histograms. 
2.2.5 Quantitative real-time PCR 
Relative gene expression was performed to use 7900HT Fast Real-time PCR System 
(Applied Biosystems, Foster City, CA, USA) [93]. TaqMan® gene expression assays for 
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EGR2 (Assay ID; Hs00166165_m1) was used, respectively. In brief, total RNA samples 
were obtained from SU-DHL-10 cells, which were treated with TAS05567 for 8 h, and 
then cDNA samples were synthesized. PCR reaction mixture was prepared with 
2×TaqMan® Fast Universal PCR Master Mix, 1 µL of the synthesized cDNA as the 
template, and each primer at a final concentration of 0.9 µmol/L. The conditions for 
real-time PCR were 1 cycle at 50ºC for 2 min and 95ºC for 10 min; and 40 cycles at 95 
ºC for 15 s and 60 ºC for 10 min. Gene expression profiling was performed using the 
comparative CT method for relative quantification. The calibration samples were 
untreated cells, and 18S ribosomal RNA was used as an endogenous control. 
2.2.6 Experimental Animals 
All animal experiments were approved by the Animal Experiments Ethics Committee 
of Taiho Pharmaceutical Co., Ltd. The animals used for the present study were male 
C.B-17 SCID mice from Charles River Laboratories Japan (Yokohama, Japan) and male 
TNP-specific IgE transgenic mice from CLEA Japan (Tokyo, Japan). All animals were 
housed in cages and maintained under a 12-h light/dark cycle with water and food 
supplied ad libitum. During the experimental period, animals were observed to assess 
activity, feeding, and signs of pain in accordance with the established protocol. For 
administration, TAS05567 was dissolved in a solution of 0.5% hydroxypropyl methyl 
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cellulose (Shinetsu Chemical, Tokyo, Japan) with 0.1 N HCl, and prednisolone was 
suspended in a solution of 0.5% HPMC without HCl.  
2.2.7 Mouse Model of Type I Allergy  
Male TNP-specific IgE transgenic mice (7 weeks old) were epicutaneously 
administered 0.025% picryl chloride (1-chloro-2,4,6-trinitrobenzene; Nakalai Tesuque, 
Kyoto, Japan) in acetone on both ears (10 µl per ear). TAS05567 was administered 
orally to mice 30 min before antigen challenge. Ear thickness was measured using a dial 
thickness gauge G-2 (Ozaki, Tokyo, Japan) at 1, 2, 4, and 24 h after antigen challenge. 
Difference in ear thickness (average value on the right and left) was calculated at each 
time point. 
2.2.8 Mouse Subcutaneous Xenograft Model 
SU-DHL-10 cells (2×107 cell) were prepared into single cell suspension in 0.1 ml of 
PBS:matrigel (Corning Incorporated, Corning, NY, USA) and injected subcutaneously 
on the flank of the mice. Mice that had tumors with an estimated volume of 
approximately 200 mm3 [the largest tumor diameter in mm × (the smallest diameter in 
mm)2 / 2] were selected and assigned to groups of five animals each by stratified 
random allocation based on individual tumor volumes so that each group had an almost 
equal mean tumor volume on day 1 of dosing. Tumor volumes were measured twice 
87 
 
weekly in vehicle-treated and TAS05567-treated groups. At the end of the experiment, 
tumor xenografts were excised, and then tumor weight was measured. Body weight was 
measured twice a week to monitor toxicity. 
2.2.9 BLNK Phosphorylation and EGR2 Gene Expression in Tumors 
  For detection of BLNK phosphorylation events in the SU-DHL-10 tumors, mice were 
sacrificed at 6 h after the first administration or 18 h after the second administration (24 
h post-first administration), followed by tumor resection. The tumor tissues 
(approximately 100 mg) were excised and dispersed by gentleMACS Dissociator 
(Miltenyi Biotec GmbH, Germany). The cells isolated from the tumor tissues were 
treated with goat F(ab’)2 Anti-Human IgG (10 µg/ml; Southern Biotech) for 10 min at 
37°C. The cells were fixed, and then incubated for 1 h at RT in the same buffer 
containing Alexa Fluor 488–labeled mouse anti-BLNK (pY84) (clone J117-1278) (BD 
Biosciences). Phosphorylation of BLNK induced by anti-IgG antibody was quantified 
using a flow cytometry using a Guava® easyCyte flow cytometry systems (EMD 
Millipore). For analysis of the gene expression of ERG2, mice were sacrificed at 14 h 
after the second administration (20 h post-first administration), followed by tumor 
resection. mRNA was extracted from the tumor tissues, and then cDNA samples were 
synthesized. Relative gene expression was performed using 7900HT Fast Real-time 
88 
 
PCR System (Applied Biosystems). TaqMan® gene expression assays for EGR2 (Assay 
ID; Hs00166165_m1) was used. The calibration samples were untreated cells, and 18S 
ribosomal RNA was used as an endogenous control.  
2.2.10 Statistical Analysis 
Statistical analysis and determination of half-maximal IC50 values were performed with 
EXSUS software, version 8.0.0 (CAC Exicare, Tokyo, Japan). Results are reported as 
mean ± SD for in vitro experiments or mean ± SEM for in vivo experiments.  
The efficacy of TAS05567 in in vivo studies was evaluated using Dunnett’s test. In all 
analyses, P<0.05 was considered to indicate statistical significance. 
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2.3 Results 
2.3.1 TAS05567 Inhibits IgE-Dependent Cellular Functions 
Syk-deficient mast cells from inducible Syk knockout mice generated using the 
Cre/loxp system showed no calcium flux or histamine release despite activation of 
FcεRI [94]. Therefore, we evaluated the ability of TAS05567 to block FcεR-mediated 
cellular functions by examining its effect on antigen-induced calcium flux and 
histamine release in IgE-sensitized RBL-2H3 cells (rat basophilic cells). As shown in 
Figure 12A and 12B, TAS05567 suppressed both calcium flux (IC50, 27 nM) and 
histamine release (IC50, 13 nM) induced by cross-linking of FcεRI with IgE and 
antigen. 
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Figure 12. IgE-mediated functional activity of TAS05567 in basophilic cells.  
(A) RBL-2H3 cells were treated with anti-DNP IgE for 1 h. Calcium 6 kit dye and 
TAS05567 were added and incubated for 2 h, followed by stimulation of cells with 
DNP-BSA. Monitoring of RFUs was as described in the Materials and Methods section. 
(B) RBL-2H3 cells were treated with anti-DNP IgE for 1 h. The sensitized cells were 
then pretreated with TAS05567 for 1 h, then stimulated with DNP-BSA for 15 min. 
Histamine content in the supernatant was measured using a histamine EIA kit. Data are 
presented as mean ± SD. 
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2.3.2 TAS05567 Attenuates IgE Cross-linking–induced Skin Lesions in TNP-IgE 
Transgenic Mice  
In the cell-based assay, TAS05567 inhibited histamine release from IgE-sensitized 
RBL2H3 cells stimulated with antigen (Figure 12B). We therefore evaluated the effects 
of TAS05567 on IgE-dependent allergic reactions in vivo using TNP-IgE transgenic 
mice. Administration of picryl chloride to the ears of TNP-IgE transgenic mice 
provoked ear swelling, which reached a peak 2 h after antigen challenge (immediate 
phase), and swelling was observed even after 24 h (late phase) (Figure 13). TNP-IgE 
transgenic mice were treated orally with a single dose of TAS05567 (10 mg/kg or 25 
mg/kg) 30 min before antigen challenge. As shown in Figure 13, TAS05567 strongly 
suppressed ear swelling from 1 to 4 h after challenge but did not show any significant 
effect on swelling at 24 h. 
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Figure 13. TAS05567 blocks the increase in ear thickness in TNP-IgE transgenic mice. 
TNP-specific IgE transgenic mice were treated with TAS05567 (10, 25 mg/kg) 30 min 
before epicutaneous administration of 0.025% picryl chloride. Ear thickness was 
measured at 1, 2, 4, and 24 h after antigen challenge. Difference in ear thickness 
(average value on the right and left) was calculated at each time point. Data are 
presented as mean ± SEM (n=6 per group) * P<0.05 and ** P<0.01 compared with the 
vehicle group. 
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2.3.3 TAS05567 Inhibits Cell Cycle Progression and Proliferation of DLBCL cells 
Through Syk-mediated Signaling Pathway 
  Syk is expressed in multiple DLBCL cell lines and activated in primary DLBCL 
tissues. Additionally, the proliferation of Syk siRNA-transfected cells is suppressed in 
some DLBCL cells [42]. Based on these evidences, we evaluated the inhibitory effects 
of TAS05567 on 5 DLBCL cell lines at a wide range of concentrations (Figure 14). We 
repeated the same experiment twice and obtained almost the same results. Among these 
cell lines, Pfeiffer and SU-DHL-10 had IC50 values below 100 nM (Table 7); 
SU-DHL-5, SU-DHL-6, and, DOHH2 had IC50 values between 100 nM and 300 nM in 
both experiments.  
Following these results, we next analyzed cell cycle progression of DLBCL cells in 
the presence of TAS05567. We focused on SU-DHL-10 cells for subsequent 
experiments, because this cell line responded well to TAS05567 in the cell proliferation 
assay as shown in Figure 14 and enabled in vivo experiments due to developing tumor 
nodules after subcutaneous injection of SU-DHL-10 cells to mice (data not shown). As 
shown in Figure 15A and 15B, the fraction of cells in the S phase was reduced by 24 h 
and 72 h treatment of cells with increasing doses of TAS05567. Percentages of cells in 
sub-G1 phase and G1 phase were increased in a concentration-dependent manner by 
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treatment with TAS05567. These results suggest that TAS05567 caused cell-cycle arrest 
at the sub-G1/G1 phase in SU-DHL-10 cells.  
We further determined whether TAS05567 inhibited the Syk downstream pathway in 
SU-DHL-10 cells. Tyrosine 525/526 on Syk is an auto-phosphorylation site and 
phosphorylation of its residues is observed in several DLBCL cell lines as well as 
primary DLBCL tissues [42]. Therefore, we measured the levels of phosphorylation at 
Y525/526 on Syk induced by IgG in SU-DHL-10 cells. As shown in Figure 16A, 
pretreatment of the cells with TAS05567 reduced the levels of Syk phosphorylation in 
the presence of IgG, and its IC50 value was 25 nM. We also evaluated the inhibitory 
effects of TAS05567 on IgG-induced phosphorylation of BLNK, a downstream of Syk 
kinase. Pretreatment with TAS05567 dramatically decreased the levels of its 
phosphorylation in a concentration-dependent manner and the IC50 value was 9.7 nM 
(Figure 16B). In comparison with TAS05567, R406 showed markedly weaker inhibition 
of IgG-induced BLNK phosphorylation in SU-DHL-10 cells, similar to the results using 
Ramos cells, another B cell line. (IC50, 380 nM; data not shown). We further assessed 
the effectiveness of TAS05567 against expression of EGR2, which was identified as a 
downstream gene regulated by the BCR pathway [95]. TAS05567 strongly suppressed 
EGR2 gene expression in SU-DHL-10 cells (Figure 16C), which was comparable to the 
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inhibition observed in the assay for Syk activity. 
 
 
 
 
 
 
Figure 14. TAS05567 exhibits broad antiproliferative activity across various DLBCL 
cell lines in vitro.  
DLBCL cell lines were treated with various concentrations of TAS05567 for 72 h. 
Cellular proliferation was determined via ATP quantification using the Cell Titer Glo 
assay. The same experiments were performed twice. Left graph shows the results of 1st 
experiment and right graph shows the results of 2nd experiment, respectively. Values are 
presented as percent of mean fluorescence intensity relative to vehicle control cells 
(100%) and non-stimulated control cells (0%). Data are presented as mean. 
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Table 7. IC50 values of DLBCL cell lines for TAS05567. 
Cell 
IC50 (nM) 
1st  2nd 
SU-DHL-5 180 130 
SU-DHL-6 160 130 
SU-DHL-10 69 80 
DOHH2 210 210 
Pfeiffer 67 59 
   
Values are mean for the IC50 values. 
The same experiments were performed twice. 1st indicates first experiment and 2nd 
indicates second experiment, respectively. 
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Figure 15. TAS5567 increases the percentages of cells in G1 phase and sub-G1 phase in 
a concentration-dependent manner.  
(A) Representative histograms of cell cycle analysis at 24 h or 72 h incubation. 
SU-DHL-10 cells were treated with different concentrations of TAS05567 for 24 h or 72 
h and cell cycle progression was examined by flow cytometer. Propidium 
iodide-labelled nuclei were analyzed for DNA content. (B) The bar diagram shows the 
percentage cell populations in the sub-G1 apoptotic population as well as the G1, S and 
G2/M phase populations of TAS05567 treated SU-DHL-10 cells. Analysis of cell 
number % of each cell cycle phase relative to total phases. 
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Figure 16. TAS5567 blocks BCR-mediated signaling cascades in SU-DHL-10 cells.  
SU-DHL-10 cells were activated with anti-human IgG antibody for 10 min in the 
presence of increasing concentrations of TAS05567. The phosphorylation levels of Syk 
were analyzed by ELISA (A) and the phosphorylation levels of BLNK were analyzed 
by flow cytometry. (C) SU-DHL-10 cells were treated with different concentrations of 
TAS05567 for 8 h. The reaction of RT-PCR was performed using the 7900HT Fast 
Real-time PCR System. Gene expression profiling was performed using the 
comparative CT method for relative quantification.  The calibration samples were 
untreated cells, and 18S rRNA was used as an endogenous control. Data are presented 
as mean. 
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2.3.4 TAS-5567 exhibits antitumor activity in SU-DHL-10 xenograft models 
without body weight loss 
Next, to verify the in vivo antitumor activity of TAS05567 in the animal model, 
SU-DHL-10 cells were injected into the subcutaneous tissue of SCID mice. When the 
tumor volume reached approximately 200 mm3, mice were randomized into three 
groups, and then 12.5 or 25 mg/kg/day of TAS05567 was orally administered for 14 
days twice daily to the mice. TAS05567 (25 mg/kg) was associated with 62% inhibition 
of tumor growth compared with vehicle-treated mice at day15 (Figure 17A). Tumors 
from TAS05567 (25 mg/kg)-treated mice weighed significantly less than those from 
vehicle-treated mice, whereas low-dose with TAS05567 did not show significant effects 
(Figure 17B). No significant effects on body weight (Figure 17C) or signs of toxicity 
were observed in any of the treatment groups. 
To determine the ability of TAS05567 to penetrate the tumor and exert its inhibitory 
activity against the Syk-mediated signaling pathway in vivo, we examined the 
pharmacodynamics of TAS05567 in SU-DHL-10 xenograft model. Phosphorylation of 
BLNK (Y84) in SU-DHL-10 tumors was detected following oral administration of 
vehicle or TAS05567 at effective dose (25 mg/kg). A single dose of TAS05567 resulted 
in approximately 95% inhibition observed at 6 h post dose (Figure 18A). Even at 18 h 
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post-second administration (24 h post-first administration) of TAS05567, the levels of 
BLNK phosphorylation were decreased by approximately 75%. Therefore, the 
Syk-mediated signaling pathway within the tumors was assumed to be suppressed 
continuously by more than 75% by treatment dose and schedule in the present study. 
Consistent with the inhibitory effects on the BLNK phosphorylation, the expression 
levels of EGR2 gene were also decreased by more than 85% at 14 h after the second 
administration (20 h post-first administration) of TAS05567 (Figure 18B).  
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Figure 17. TAS05567 significantly reduces proliferation of SU-DHL-10 cells in vivo.  
SU-DHL10 cells were implanted subcutaneously in SCID mice. Tumors were 
established to about 200 mm3 in size before randomization in three groups for efficacy 
studies. Vehicle, TAS05567 (12.5 mg/kg) or TAS05567 (25 mg/kg) was then 
administered orally twice daily to mice for 14 days. TAS05567 slowed down tumor 
growth, as demonstrated by monitoring tumor volume change (A) and by measurement 
of tumor weight on day15 (B). As an indicator of toxicity, the mean of body weight 
change was calculated for each group (C). Data are presented as mean ± SEM (n=5 per 
group). ** P<0.01 compared with the vehicle group. 
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Figure 18. TAS05567 suppresses phosphorylation of BLNK and expression EGR2 gene 
in SU-DHL-10 tumors 
Mice bearing established SU-DHL-10 tumors were treated with vehicle or TAS05567 
(25 mg/kg) twice daily. The second administration was conducted at 6 h after the first 
administration. Tumors were collected at 6, 20, and 24 h after the administration of 
vehicle or TAS05567. (A) For analysis of phosphorylation of BLNK, the tumor tissues 
were dissociated, and then stimulated with anti-mouse IgG antibody for 10 min. The 
phosphorylation levels of BLNK in the suspended cells were analyzed by flow 
cytometry. Values are presented as percent of mean fluorescence intensity relative to 
vehicle-treated tumor cells stimulated with anti-IgM antibody (100%) and 
vehicle-treated tumor cells with no stimulation (0%). (B) For analysis of gene 
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expression, mRNA was extracted from the tumor tissues. The expression levels of 
EGR2 mRNA were determined by quantitative real-time PCR. The calibration samples 
were untreated cells, and 18S rRNA was used as an endogenous control. Values are 
presented as percent of mean EGR2 gene expression relative to vehicle-treated tumor 
cells (100%). Data are presented as mean ± SEM (n= 4 per group). 
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2.4 Discussion 
We demonstrated that TAS05567 suppressed antigen-induced calcium flux as well as 
histamine release in IgE-sensitized basophilic cells. In addition, TAS05567 
concentration-dependently inhibited cell proliferation of several DLBCL cell lines, and 
blocked Syk-mediated signaling pathway as well as cell cycle progression in 
SU-DHL-10 cells, which are highly sensitive to this compound. When TAS05567 orally 
was administered to TNP-IgE transgenic mice, the ear swelling induced was 
significantly suppressed in immediate phase after antigen exposure. Furthermore, 
TAS05567 significantly inhibited the tumor growth of mice with SU-DHL-10 xenograft 
and markedly reduced the levels of BLNK phosphorylation and EGR2 gene expression 
within the tumor tissues at effective dose, when compared to vehicle control. 
Type 1 allergic diseases, including urticaria, asthma, and allergic rhinitis, are caused 
and exacerbated by IgE-mediated allergic reactions [28, 29]. Antigen-specific IgE 
bound to FcεRI on mast cells induces the release of chemical mediators such as 
histamine, causing the early symptoms of an allergic reaction [30]. Therefore, the 
symptoms of type 1 allergic diseases are typically alleviated with antihistamine drugs. 
As Syk acts upstream of signaling cascades induced by IgE cross-linking, TAS05567 
potently inhibited the antigen/IgE-triggered intracellular calcium flux as well as 
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histamine release in vitro (Figure 12A and 12B). We further demonstrated the ability of 
TAS05567 to suppress immediate IgE-mediated allergic reactions in vivo using 
TNP-specific IgE transgenic mice. Unexpectedly, TAS05567 did not show a significant 
response in the late phase. One possible reason might not be enough concentration of 
TAS05567 to suppress the inflammation in this phase because its concentration at 24 h 
after the administration was lower than IC50 value of the whole blood assay even at 25 
mg/kg (data not shown). Another possible reason is that IgE-mediated chemical 
mediator secretion through Syk activation contributes to the immediate allergic response, 
but the delayed response might depend on other signaling cascades (e.g., T-cell receptor 
signaling). Indeed, the immediate ear swelling caused by epicutaneous antigen 
challenge in this mouse model can be attributed primarily to a series of chemical 
mediators, including histamine, and thus, administration of an antihistamine inhibitor 
blocks the allergic response within a few hours post–antigen challenge. However, the 
antihistamine agent does not improve symptoms in the late phase, whereas cyclosporine 
A markedly inhibits ear swelling only in this phase [96]. As regards inhibition of 
immediate allergic responses, TAS05567 might be more potent than conventional drugs 
that target a single chemical mediator because Syk inhibition concomitantly suppresses 
secretion of multiple factors from mast cells, including histamine, arachidonate 
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metabolites, and cytokines [97]. From these findings, we expect that combination 
therapies including TAS05567 and inhibitors targeting T-cell function, such as 
cyclosporine A, will prove highly efficacious in the treatment of type I allergic diseases. 
Since chronic activation of BCR signaling pathway has been reported to be 
implicated in the pathogenesis of a variety of B-cell malignancies, such as DLBCL, Syk 
kinases is expected to be an attractive drug target for therapy of these malignancies [41, 
42]. In the present study, we first evaluated the inhibitory effects of TAS05567 on the 
cell proliferation using 5 cell lines of DLBLC in vitro, because DLBCL is generally and 
clinically considered a heterogeneous collection of malignancies [98]. Here, we 
demonstrated that TAS05567 suppressed the cell proliferation of all the cell lines in a 
concentration-dependent manner (Figure 14). Based on the cell-of-origin subtypes, 
DLBCL are further divided into germinal center B-cell (GCB) and non-GCB activated 
B-cell subtypes (ABC), with nearly 50% of cases being classified as the former subtype 
[99, 100]. All of the DLBCL cell lines we used were GCB subtype cells, as these cells 
are commercially available products. In general, ABC DLBCL is associated with 
considerably worse outcomes when treated with standard therapy (R-CHOP) and an 
inferior prognosis than GCB DLBCL [101, 102]. However, according to a report by 
Cheng et al., the effectiveness of Syk inhibitors against DLBCL cell lines of ABC 
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subtype has not seemed to be weaker than that against the cell lines of DLBCL subtype 
[42]. Hence, to clarify the possibility of TAS05567 as a therapeutic drug for patients 
suffering from DLBCL, we need further study to evaluate the inhibitory effects of 
TAS05567 on the proliferation of ABC DLBCL cells, such as HBL-1 or SU-DHL-2. 
Moreover, we examined a molecular mechanism underlying the effects of TAS05567 
against the proliferation of SU-DHL-10 cells in vitro. TAS05567 not only decreased the 
levels of phosphorylation of Syk and BLNK as well as gene expression of EGR2, a 
factor regulated by BCR pathway, but also arrested cell cycle progression in the G1 
phase, suggesting that these may cause repression of the proliferation of the cells. 
In the in vivo antitumor activity study using SU-DHL-10 tumor-bearing mice, 
TAS05567 was orally administered twice daily at 12.5 mg/kg or 25 mg/kg to the mice 
for 14 days. While TAS05567 at 25 mg/kg showed a statistically significant tumor 
growth inhibition on day 15, treatment with low dose of TAS05567 exhibited a 
moderate inhibitory effect on the tumor growth and did not reach statistically significant 
(Figure 17A and 17B). The above data were unexpected, because TAS05567 
ameliorated the symptoms in models of RA and ITP at less than 12.5 mg/kg. We are 
speculating on two possibilities why TAS05567 had a different response between 
anti-inflammatory effect and anti-tumor activity in vivo. One possible cause is that 
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tumor microenvironment may influence the antitumor activity of TAS05567 and the 
growth of subcutaneous SU-DHL-10 tumors in mice. The tumor microenvironment 
consists of a variety of stromal cells, endothelial cells, extracellular matrix, immune 
regulatory cells, growth factors, and cytokines that interact with cancer cells, which 
contributes to treatment resistance and tumor progression [103, 104]. In the present 
study, the immune regulatory cells, such as regulatory T cells, may have little influence 
on the tumor progression because of the use of severe immune deficient mice. However, 
the stromal cells and endothelial cells within the SU-DHL-10 tumors can produce 
growth factors and angiogenic factors cause accelerated neoangiogenesis and tumor 
progression, which may result in the attenuation of the antitumor efficacy by treatment 
of TAS05567. We suppose that the antitumor activity of TAS05567 may not be 
markedly enhanced by increasing the dose (> 25 mg/kg) or the frequency (three times 
daily) of our compound, because the level of BLNK phosphorylation within the tumor 
was already decreased by over 75% after 24 h of TAS05567 treatment at 25 mg/kg 
twice per day. Therefore, TAS05567 alone may fail to achieve complete tumor 
regression in vivo. R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, 
prednisone) remains the standard of care for newly diagnosed DLBCL due to limited 
therapeutic options, even though approximately 30 to 40 % of patients develop relapsed 
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or refractory disease [90, 105, 106]. Now, we are investigating the effects of TAS05567 
in combination with vincristine, doxorubicin, or prednisolone on the tumor growth in 
vitro as well as in vivo, and appropriate combination therapeutic strategies considering 
efficacy and safety will be determined in the future. The other possible cause is that we 
used the subcutaneous xenograft model in our experiment. Considering the origin of 
SU-DHL-10, a human B-cell malignant cell line, we should establish an orthotopic 
SU-DHL-10 xenograft model in mice, but we could not do that technically. In general, 
the hematopoietic cell microenvironment, including bone marrow stromal cells and 
resident macrophages, affects the growth and survival of lymphoma cells [107]. The 
growth rate of SU-DHL-10 cells in vivo may be difference between subcutaneously 
transplanted tumors and orthotopically transplanted tumors, because these 
tumor-supportive environments are not same. Recently, some orthotopic xenograft 
models have been established by transplanting lymphoma cells into hematopoietic 
organs, such as spleen, or intravenously into the irradiated mice [108, 109]. Therefore, 
we are currently developing an orthotopic transplantation model of SU-DHL-10 cells in 
mice, and will plan to evaluate the antitumor efficacy of TAS05567 using the orthotopic 
xenograft model. 
Taken together, these results in this chapter suggest that TAS05567 may be a 
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promising new therapeutic option for patients with type 1 allergic diseases, such as 
atopic dermatitis, as well as B-cell malignancies, such as DLBCL. 
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Conclusion 
 
In the present research, the pharmacological characteristics of TAS05567, a novel 
inhibitor of Syk kinase, were investigated for the purpose of developing a new 
therapeutic agent for the treatment of autoimmune and type 1 allergic diseases, and 
B-cell malignancies.  
In Chapter 1, we first examined the potency and selectivity for kinases, receptors, 
channels, Ig-mediated intracellular, and cellular functional activity of TAS05567 by in 
vitro experiments using R406 as a comparison agent. TAS05567 potently inhibited Syk 
enzymatic activity with IC50 values of 0.37 nM (ATP concentration at Km level) and 
1.5 nM (ATP concentration at the cellular level), but it only showed >70% inhibition of 
Syk and 4 other kinases among 192 kinases at 50 nM. In addition, TAS05567 showed at 
least 10-fold selectivity for Syk over JAK2, VEGFR2, FLT3, and RET, but R406 
showed equal or greater efficacy against these kinases. TAS05567 only inhibited 1 of 
the 68 non-kinase targets tested at 10µM. Cell-based assays revealed that TAS05567 
exhibited stronger inhibition of the IgM-induced phosphorylation of BLNK, PLCγ2, 
and Erk1/2 in B cells compared to R406. Moreover, FcγR-mediated TNF-α production 
as well as phagocytic activity, and mature osteoclast differentiation from precursor cells 
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were inhibited by treatment of TAS05567 in a concentration-dependent manner. As 
good absorption of TAS05567 was observed in both mice and rats following single dose 
oral administration of it, the in vivo efficacy of TAS05567 was evaluated in preclinical 
animal models of RA as well as ITP. The dose of TAS05567 for the in vivo experiments 
was estimated from the integration of the whole-blood assay data with single-dose 
pharmacokinetic data. When given prophylactically to mice with CAIA and mice with 
CIA, TAS05567 showed clear dose-dependent anti-inflammatory effects. Treatment 
with TAS05567 (> 10 mg/kg) or R406 resulted in a significantly reduction of paw 
volume and attenuated cartilage damage as well as bone destruction in rats with CIA 
when compared with the vehicle control despite the therapeutic regimen. Of note, while 
TAS05567 did not significantly change the red blood cell count or hemoglobin level in 
any dose group, R406 showed a statistically significant both parameters. Furthermore, 
both TAS05567 and R406 provided a significant protection against thrombocytopenia 
induced by anti-CD41 antibody in mice. However, when administered at 100 mg/kg, 
TAS05567 completely prevented thrombocytopenia, whereas R406 only partially 
prevented it. Based on these findings, TAS05567 would provide a better balance 
between efficacy and safety than R406 as a novel therapy for the treatment of 
autoimmune diseases.  
113 
 
In Chapter 2, we examined the effectiveness of TAS05567 on non-autoimmune 
diseases, including type 1 allergic diseases and DLBCL, caused by aberrant Ig 
production or BCR signaling cascade are involved in the pathogenesis. TAS05567 
blocked the IgE receptor cross-linking-induced calcium flux and histamine release from 
basophilic cells. Besides the in vitro experiments, TAS05567 also suppressed the 
antigen-provoked ear swelling, a representative type 1 allergic reaction, in TNP-IgE 
transgenic mice at the same dosage that exhibited anti-inflammatory effects of it on 
autoimmune disease models. DLBCL, one of the B-cell malignancies, is mainly caused 
by chronic activation of BCR signaling pathway, and this disease is a heterogeneous 
both clinically and morphologically [41, 98, 110]. When we evaluated the inhibitory 
effects of TAS05567 on the cell proliferation using five cell lines of DLBCL, our 
compound showed good efficacy against the growth of all the cells. Additionally, 
treatment with TAS05567 resulted in the suppression of the phosphorylation levels of 
Syk and BLNK, the decrease of the expression of EGR2 mRNA, and the induction of 
cell cycle arrest in SU-DHL-10 cells. Further, TAS05567 significantly reduced the 
tumor growth of SU-DHL-10 xenografts in mice, although they received a higher total 
dose compared to the mice with inflammatory diseases. The BLNK phosphorylation and 
EGR2 gene expression within the tumor tissues were strongly inhibited following 
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treatment with TAS05567 at effective dose. 
 Currently, anti-TNF agents and JAK inhibitors as treatment for rheumatoid arthritis, 
and anti-IL-4 receptor antibody and calcineurin inhibitors as treatment for type 1 
allergic diseases including atopic dermatitis have not only shown promising results in 
the clinical trials but also had superior efficacy to the conventional therapies in the 
real-world clinical practice. However, unfortunately, not all patients with above 
disorders benefit from these current treatment approaches, and therefore, many patients 
who do not shown a complete response to them have required new therapy options with 
a different spectrum of activity from the existing treatments. Since Syk is expressed in a 
variety of immune cells, such as B cells, macrophages, monocytes, mast cells, 
neutrophils, and osteoclasts, the inhibitors of Syk may exert a potent anti-inflammatory 
action in various diseases by different mechanisms from JAK inhibitors or calcineurin 
inhibitors mainly targeting the activated T cells. Furthermore, as TAS05567 is expected 
to be well tolerated due to highly selective blockade of Syk activity, the combination 
therapy of our compound and the existing drugs, including JAK inhibitors or tacrolimus, 
may offer great benefit for patients with RA or type 1 allergic diseases who fail the 
conventional therapies. In 2018, for the first time as an inhibitor of Syk kinase, 
Fostamatinib was approved by FDA as a therapeutic drug for patients with chronic ITP 
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[111]. Nevertheless, according to the results of Phase 3 trials, more than half of the 
patients have not shown any satisfactory response to this drug, and several adverse 
events, such diarrhea, hypertension, nausea, and transaminase elevation were observed 
similarly to past phase 2 studies of ITP [55]. Consequently, novel Syk inhibitors like 
TAS05567 with highly selective and exquisitely potent anti-inflammatory properties are 
required as new ITP therapeutic interventions. DLBCL is the most common NHL, 
accounting for 30–40% of NHL cases [112]. While R-CHOP is the current first-line 
standard treatment for patients with DLBCL, nearly 40% of patients will relapse or 
refractory disease following the initial therapy, indicating the need for alternative 
treatment approaches the decrease the risk of recurrence. While other types of Syk 
inhibitors, such as Cerdulatinib, a Syk/JAK dula inhibitor, and TAK-659, a Syk/Flt3 
dual inhibitor, have been developed for patients with DLBCL, they are concerned about 
the side effects related to their selectivity towards protein kinases except for Syk [92, 
113, 114]. From the view point of the psychological and physiological conditions of 
patients who have received the prior combination chemotherapy, we believe that 
alternative drugs with fewer side effects are much desired. In that sense, TAS 05567, 
which is a highly selective inhibitor for Syk, is expected to be well tolerated and 
provide excellent efficacy in patients with DLBCL by using it alone or in combination 
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with R-CHOP therapy. Recently, Ibrutinib, an irreversible inhibitor targeting Bruton's 
tyrosine kinase (Btk), another downstream molecule of BCR signaling pathway, has 
shown significant clinical benefit in patients with B-cell malignancies, including 
DLBCL, follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM) [115]. 
However, it has been reported that mutation of C481S in Btk resulted in loss of Ibrutinib 
binding and restoration of Btk activity in the presence of this drug, subsequent 
reactivation of BCR signaling, eventually leading to clinical relapse [116]. On the 
contrary, as Syk is thought to be activated upstream of Btk in the BCR signaling cascade 
[117], TAS05567 may provide a clinical benefit for patients with B-cell malignancies 
harboring BtkC481S mutation through the blockade of Syk activity. 
Taken together, in this study we demonstrate that TAS05567, a novel highly selective 
and potent inhibitor of Syk, would provide an effective therapy for a broad range of 
disorders, including autoimmune diseases, type 1 allergic diseases, and DLBCL. 
Considering the enormous results from the past clinical trials in which many patients 
have not shown substantial clinical benefit or fail to achieve complete remission in the 
above-mentioned diseases, alternative treatment strategies are urgently desired for these 
patients. We expect that our findings obtained by this study will lead to new treatment 
options for patients suffering from inflammatory diseases as well as B-cell 
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malignancies. 
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